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ABSTRACT 
 Advanced prostate cancer (PCa) treated with androgen deprivation therapy (ADT) 
eventually relapses to an ADT-resistant disease referred to as castration resistant PCa 
(CRPC). Recent integrative analyses of PCa genomes have led to the elucidation of 
potential subtypes that are revelatory to the development of PCa as well as the 
mechanisms of resistance to ADT and CRPC progression. These studies have confirmed 
that alterations in the androgen receptor (AR) signaling axis are central to CRPC 
progression, and have uncovered complex mechanisms by which AR and other 
components of the AR signaling axis affect, and are affected by, genomic changes and 
epigenetic transformations. Among the most frequent alterations in CRPC are direct 
alterations in the AR gene. These AR gene alterations include AR amplification, point 
mutations, and more recently AR gene rearrangements leading to expression of truncated, 
constitutively active AR splice variants that are impervious to ADT.  Fortunately, the 
recent development of transcription activator-like effector nucleases (TALENs) has 
allowed researchers to tailor the genomes of their model systems more rigorously than 
ever before.   
This dissertation presents studies centered on genome engineered cell lines 
modeling intragenic-AR rearrangements that are associated with the production of 
androgen receptor splice variants.  In the second chapter, two AR rearrangements 
associated with ARv567es expression were recreated in PCa cell line R1-AD1 using 
targeting nucleases.   These engineered cell lines expressed high levels of Arv567es that 
recapitulated the full length AR transcriptome and drove androgen independent growth.   
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In chapter three, AR rearrangements associated with high AR-V7 expression in 
CRPC cell lines CWR-R1 and 22Rv1 were induced and gene-corrected, respectively, 
using targeting nucleases.  We found that a deletion contained in AR intron 1 of CWR-R1 
was not sufficient to induce AR-V7 expression.  However, genetic correction of a 
duplicated AR intron 3 region found in 22Rv1 decreased AR-V7 levels.  These models 
were developed to determine the underlying mechanisms of AR variant production as 
well as provide a novel platform with which to study AR variant DNA binding, 
transcriptional regulation, and clinically relevant aspects of PCa such as biomarker 
research and precision medicine.   
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CHAPTER 1: General Overview 
1.1 Introduction 
 Prostate cancer (PCa) is the most frequently diagnosed male cancer and second 
leading cause of male cancer deaths in the USA (Siegel et al, 2013). The androgen 
receptor (AR) is a master regulator transcription factor in cells of prostatic lineage, and 
this master regulator function is maintained in PCa cells (Garraway et al, 2006).  The 
frontline treatment for locally advanced or metastatic PCa involves androgen deprivation 
therapy (ADT), which is achieved by blocking androgen production 
(surgical or chemical castration with LHRH agonists) or directly antagonizing the AR 
(antiandrogens). A major limitation is that castration-resistant or castration-recurrent 
prostate cancer (CRPC) results within 2–3 years due to alterations in the androgen/AR 
signaling axis. This limitation has begun to be addressed through mechanistic 
understanding of the changes to androgen/AR signaling that occur during disease 
progression. For example, it is now established that AR activity persists in CRPC despite 
ongoing ADT, and the AR signaling axis remains a viable therapeutic target for treating 
CRPC patients. New therapies that have been developed to re-target AR ligand binding 
and extend the lifespan of patients with CRPC include the cytochrome P450 c17 
(CYP17) inhibitor abiraterone acetate (de Bono et al, 2011), which inhibits androgen 
synthesis in testes, adrenals, and tumor tissue as well as the next generation antiandrogen 
enzalutamide (Scher et al, 2012), which suppresses AR transcriptional activity even 
under conditions of AR overexpression.  
Despite these clinical successes, the development of resistance to abiraterone and 
enzalutamide, and ongoing disease progression for many patients, remains a major 
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challenge. A greater appreciation of the complex genomic events involved in the 
initiation and progression of PCa is expected to yield insights into risk and likely routes 
of therapy resistance taken by individual cells in heterogeneous tumor populations. This 
could facilitate the individualization and optimization of treatment regimens, which are 
cornerstones in the concept of precision medicine. To this end, many studies investigating 
the PCa genome have identified disease- and/or progression-specific alterations in genes 
that impact the signaling and regulation of the androgen/AR signaling axis. Importantly, 
included in this list are a myriad of alterations in the AR gene at Xq11-12, which directly 
alter the regulatory dynamics and biological function of the AR. 
 
1.2 Genomic aspects of Prostate Cancer 
1.2.1 Recurrent Genomic Alterations in Prostate Cancer  
Gene fusions between the AR-regulated TMPRSS2 gene promoter and the coding 
region of ETS− family transcription factors, including ERG and ETV1, are among the 
most frequent recurrent alterations in PCa. These fusions render ETS transcription factors 
androgen-responsive and under direct control of the AR signaling axis in PCa cells. Their 
existence in the earliest precursor lesions indicates that these are initiating drivers of PCa 
and efforts are being made to translate this knowledge into better diagnostic tools and 
new targeted therapies (Rubin et al, 2011).   
Knowledge of the broader genomic landscape of PCa has been greatly expanded 
in recent years by integrative whole-genome analyses using algorithms that coordinate 
datasets derived from studies of genome-wide copy number, exome sequence, mRNA 
expression, and epigenetic modification. These analyses have provided insights into the 
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mechanisms by which mutations, epigenetic changes, and genome rearrangements 
conspire to dysregulate genes and pathways in PCa. For example, a recent integrative 
study demonstrated that the p53/RB pathway was disrupted in 34 % of primary, 
hormone-naïve PCa and 74 % of CRPC metastases, the PTEN/PI3K pathway was 
disrupted in 42 % of primary PCa and 100 % of CRPC metastases, and the RAS/RAF 
pathway was disrupted in 43 % of primary PCa and 90 % of CRPC metastases (Taylor et 
al, 2010).  Similar integrative studies have found that MYC, WNT, FOXA1, SPOP, 
MLL2, CHD1, and NCOA2 are frequently affected by copy number alterations or point 
mutations (Grasso et al, 2012; Friedlander et al, 2012; Berger et al, 2011; Beltran et al, 
2012).  Moreover, these integrative studies have revealed that AR copy number 
alterations and point mutations do not occur in primary PCa, but occur in 58% of CRPC 
metastases (Talor et al, 2010).  However, when the broader AR signaling axis was 
considered, alterations were observed in 56 % of primary PCa and 100 % of CRPC 
metastases, confirming that this master regulator is among the most  frequently altered 
pathways in PCa. 
  While these integrative studies have revealed important biological insights into 
PCa, they have relied on targeted approaches that may not reveal the full spectrum of 
genomic alterations that could occur during disease development and progression. 
Indeed, recent whole-genome sequencing of seven primary PCa specimens and matched 
normal tissues demonstrated that important genomic events in PCa are likely 
underappreciated due to the limitations of targeted approaches such as CGH and exome 
sequencing. The most striking finding from PCa whole-genome sequencing was the high 
prevalence of copy number neutral, or balanced, translocations and inversions among the 
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median 90 rearrangements per genome. (Berger et al, 2012).   Some of these  
rearrangements had interrupted tumor suppressor genes such as PTEN and p53, which 
would be expected to activate oncogenic signaling through PI3K/Akt and RB pathways, 
respectively (Berger et al, 2012).  It is also interesting to note that some loci did not 
appear to undergo copy number loss even though inversions and/or point mutations were 
commonly observed, whereas other loci were frequently deleted (Grasso et al 2012, 
Berger et al 2011).  This suggests that specific chromatin configurations and/or genome 
architectures may be required for activation or inactivation of genes harbored within 
these affected regions. 
 
1.2.2 Role of AR in the Genesis of Rearrangements in the PCa Genome  
These integrative and whole-genome sequencing studies have raised an intriguing 
question: why is there a propensity towards structural alteration in the PCa genome? For 
TMPRSS2–ERG rearrangement-positive cancers, rearrangement breakpoints appear to be 
enriched near sites of AR and/or ERG binding with open chromatin histone marks, 
indicating that active transcription driven by these transcription factors may create 
chromatin environments that are prone to breakage (Berger et al, 2011).  There is also 
gathering evidence to support the notion that AR binding strongly influences higher-order 
chromatin structure and three-dimensional organization of the nucleus in PCa cells, 
which may favor genesis of specific rearrangement events by enhancing proximity of 
discrete genomic domains (Wang et al, 2007; Mani et al, 2009; Lin et al, 2009).  
The best evidence supporting a role for AR in shaping deterministic genomic 
events in the natural history of PCa progression comes from work investigating the 
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mechanisms underlying recurrent TMPRSS2–ERG fusions. TMPRSS2 expression is 
controlled by an AR-driven enhancer element just upstream of the TMPRSS2 promoter 
(Wang et al, 2007).  This TMPRSS2 locus is 3 Mb upstream of ETS family transcription 
factor ERG on chromosome 21. FISH-based studies with molecular probes targeting 
regions 5′ to the TMPRSS2 breakpoint and 3′ to the ERG breakpoint demonstrated that 
these loci are brought within close proximity in fusion-negative LNCaP PCa cells upon 
addition of the natural AR ligand, DHT (Mani et al, 2009).  DHT-induced proximity was 
also observed for the chromosomes 21 and 7 break fusion junctions of the TMPRSS2–
ETV1 gene fusion (Lin et al, 2009). Importantly, exposure of LNCaP or the normal 
prostate epithelial PrEC cell line to gamma irradiation, which induces genotoxic stress, 
synergized with DHT to induce genesis of TMPRSS2–ERG and TMPRSS2–ETV1  
fusions (Mani et al, 2009; Lin et al, 2009).  Induction of these fusion events appeared to 
require DHT/AR-mediated recruitment of various DNA-directed enzymatic activities to 
the break fusion junctions, which promoted the formation of DNA double strand breaks 
at these sites. For example, activation-induced cytidine deaminase, the ORF2 
endonuclease encoded by long interspersed nuclear elements (LINE-1), and 
topoisomerase IIB could all be recruited to these AR binding sites, and all have been 
shown to be important for generation of the fusion events (Lin et al, 2009, Haffner et al 
2010).  Importantly, DHT-induced proximity and irradiation-induced DNA damage 
were also shown to lead to generation of the SLC45A3: ETV1 fusion in LNCaP cells, 
which is a less-frequent PCa gene fusion leading to AR-mediated overexpression of 
ETV1 in a subset of PCa (Lin et al, 2009; Tomlins et al, 2007).  These data imply that 
many other less frequently occurring rearrangements between androgen regulated 
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genes and ETS family transcription factors may arise through this same mechanism 
(Rubin et al, 2011).  Importantly, these ETS family fusions may then play a role in 
promoting further instability of the PCa genome. For example, ERG overexpression 
increases DNA damage in PCa lines and ERG binding is enriched at rearrangement 
breakpoints in primary PCa, implicating ERG as a driver of subsequent genomic 
rearrangements and tumor progression (Brenner et al, 2011; Berger et al 2011).  
Epigenetic marks impart an additional layer of regulatory information on top of 
the information embedded in the PCa genome. Therefore, it is not surprising that many 
genomic studies have demonstrated that dysregulated epigenetic control accompanies the 
progression of PCa. Indeed, CRPC genomes display a general overall hypermethylation 
of CpG dinucleotides when compared with benign prostate (Friedlander et al, 2012).   
Intriguingly, DNA methylation and genomic changes appear to coordinately alter the 
regulation of the cell cycle and testosterone metabolism, providing possible specific 
mechanisms through which DNA methylation promotes PCa progression (Friedlander et 
al, 2012).       
Changes in the epigenetic regulatory environment can potentially change the 
physiology of the cancer cell and perhaps change the context in which existing and 
subsequent genomic events are manifest. One example of this is coordinate binding 
activity between AR and ERG. ERG represses AR transcriptional activity at loci involved 
in differentiation by recruiting the polycomb group (PcG) protein EZH2, which gives 
PCa cells more stem cell-like characteristics (Yu et al, 2010).  PcG proteins are 
responsible for maintaining bivalent repression domains to prevent the expression of 
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lineage genes in embryonic stem cells (Richly et al, 2011).  Another recent study 
associated shared AR and ERG binding sites with transcriptional programs relating to 
movement and cell proliferation (Chng et al, 2012).  This study further showed that 
HDAC1, HDAC2, and HDAC3 and EZH2 bound to these AR/ERG binding sites.  This 
may have clinical relevance, as HDAC 1, HDAC 2, and HDAC 3 display high expression 
levels in a majority of PCa and HDAC2 levels in PCa tissues predict shorter PSA-free 
survival (Weichert et al, 2008).   Mixed-lineage leukemia 2 (MLL2), a H3K4-specific 
histone methytransferase is mutated in 8.6% of PCas (Grasso et al, 2012).  MLL2 is also 
commonly mutated in other cancers and is involved in the regulation of many signaling 
pathways including nuclear hormone signaling (Guo et al, 2012).  Indeed, MLL2 
complex members could be immunoprecipitated with an AR antibody along with ERG 
and FOXA1 (Grasso et al 2012).  FOXA1 is mutated in 4% of PCas and is an important 
pioneer factor for the AR transcriptional program (Barbieri et al, 2012).  Interestingly, 
FOXA1 is preferentially recruited to binding sites enriched in H3K4me1/2 marks, which 
in turn influences AR binding to nearby androgen response elements (AREs) (Lupien et 
al, 2008; Lupien et al, 2009).  It is tempting to speculate that alterations in MLL2 activity 
could lead to global alterations in H3K4me1/2 marks, which could in turn affect FOXA1 
and AR binding and downstream regulatory processes in PCa cells. 
 
1.3 Truncated AR Splice Variants 
Overall, these genomic studies have demonstrated that the AR can be the 
instigator and the accomplice in effecting cascading genomic and epigenetic changes via 
chromatin interacting complex members. Interestingly, a pervasive role for the AR in 
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driving deterministic events in PCa is further evidenced by the high rate of mutation and 
gene amplification of the AR gene in CRPC. These AR gene aberrations have been 
shown to alter AR signaling and regulation as well as facilitate AR transcriptional 
activity despite administration of targeted therapies designed to inhibit the AR (Saraon et 
al, 2011; Steinkamp et al, 2009; Gottlieb et al, 2012).  For example, AR gene 
amplification leads to overexpression of AR protein, which sensitizes PCa cells to 
castrate levels of androgens, and can also elicit inappropriate agonist responses to 
antiandrogens such as bicalutamide (Chen et al, 2004).  Similarly, a myriad of point 
mutations have been described in the AR, many of which occur in the ligand binding 
domain (LBD) and broaden the repertoire of potential agonists (Gottlieb et al, 2012; 
Brooke and Bevan, 2009).  More recently, rearrangements that alter AR gene structure 
and splicing patterns have been described in PCa cell lines and xenografts (Li Y et al, 
2011; Li et al, 2012). These AR splicing alterations underlie high expression levels of 
truncated AR variants that lack the AR LBD, which is the target of AR-centered therapies 
for PCa (Fig. 1-1).  The role of AR splice variants in CRPC has been gaining importance 
in recent years due to the discovery of their prevalence in CRPC tissues (Guo et al, 2009; 
Hu et al, 2009; Hornberg et al, 2011), and their association with PCa progression and 
resistance to AR-targeted therapy (Mostaghel et al, 2011; Hu et al, 2012; Li et al, 2012).   
Truncated AR splice variants were initially discovered in CRPC cell lines derived 
from the CWR22 xenograft model of PCa progression (Guo et al, 2009; Hu et al, 2009; 
Tepper et al 2002; Dehm et al, 2008).  They are produced by aberrant splicing and 
premature translation termination, which results in synthesis of LBD-truncated, 
constitutively active forms of AR.  To date, well over a dozen discrete AR splice variants 
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have been described (Dehm and Tindall, 2011).  Identification and validation of protein 
translation of these AR variants in PCa cell lines has traditionally involved cloning the 
mRNA and designing AR variant sequence-specific siRNAs in order to achieve selective 
knock-down of that truncated AR variant (Guo et al, 2009; Dehm et al, 2008).  This 
selective knock-down strategy has also facilitated functional characterization in PCa cell 
lines that naturally express high levels of truncated AR variants, such as the 22Rv1, 
CWR-R1, and VCaP cell lines.  In these models, these strategies have revealed that 
truncated AR variants support androgen-independent expression of AR target genes, and 
drive androgen-independent growth in a manner that is resistant to anti-androgens (Guo 
et al, 2009; Hu et al, 2009; Mostaghel et al, 2011; Li et al, 2012; Sun et al, 2010). These 
key findings have highlighted the importance of understanding the role and origin of AR 
variants in clinical disease progression.  
 
1.3.1 AR Variant Splicing Mechanisms: 
Recent investigation of the mechanisms underlying the synthesis of truncated AR 
splice variants in CRPC has highlighted genomic rearrangements as a previously-
unrecognized class of alterations affecting the AR gene (Li Y et al, 2011; Li et al 2012).   
For example, our group reported that the 22Rv1 cell harbored a 32kb intragenic 
duplication of a segment encompassing AR exon 3, which harbors cryptic exons 2b, CE1, 
CE2, and CE3 (Fig. 1-1).  All of these cryptic exons have been shown to splice with high 
efficiency downstream of AR exon 3 in this cell line; therefore this rearrangement is an 
attractive explanation for these altered AR splicing patterns.  Interestingly, the CWR22Pc 
cell line is an androgen-dependent sub-line derived from the same parental CWR22 
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xenograft as 22Rv1 cells.  When CWR22Pc cells were cultured under castrate conditions, 
rare cells harboring this intragenic duplication emerged and continued to display 
enrichment over several weeks of culture in vitro.  Importantly, outgrowth of these 
duplication-positive cells coincided with increasing expression of truncated AR variant 
mRNA and protein, indicating that expression of these species was restricted to the cell 
population harboring this underlying rearrangement in the AR gene (Li Y et al, 2011).  
These data provided the first clues that alterations in AR splicing may be due to 
underlying alterations in the structure of the AR gene. 
An additional CRPC cell line in which truncated AR variants were identified and 
functionally characterized is the CWR-R1 cell line.  In these cells, expression of the AR-
V7, encoded by contiguously-spliced AR exons 1, 2, 3 and CE3, was shown to be 
enriched in CWR-R1 xenografts grown in castrated vs. intact mice (Guo et al, 2009).  We 
recently developed a strategy for paired-end massively parallel sequencing following 
hybridization-based enrichment of the AR locus, which revealed a 48kb deletion in AR 
intron 1 in these cells (Li et al, 2012).  Interestingly, quantitative analysis of this deletion 
indicated that the CWR-R1 cell line is heterogeneous, with a variable proportion of cells 
harboring this deletion.  However, long-term culture under castrate conditions resulted in 
enrichment for this deletion-positive population to near-uniformity.  As with the 22RV1 
model, the expression level of the AR-V7 variant in the CWR-R1 cell line was directly 
proportional to the percentage of cells harboring this deletion (Li et al, 2012).  Similarly, 
derivation of discrete sub-clones from this heterogeneous parental population revealed 
that high levels of truncated AR variant expression was restricted to the deletion-positive 
cell population (Li et al, 2012).  
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In addition to these CRPC cell lines, there is also strong evidence to support a role 
for AR gene rearrangements in clinical CRPC metastases and xenograft tissues derived 
from clinical CRPC metastases.  For example, deletions and duplications involving the 
AR gene directly alter gene copy number, and imbalances in copy number have been 
observed across the length of the AR gene in CRPC, but not primary prostatectomy 
specimens (Li Y et al, 2011; Li et al, 2012).  The LuCaP 86.2 xenograft was derived 
following surgical resection of a CRPC bladder metastasis (Sun et al, 2012), and this 
tumor displayed reduction in copy number for AR exons 5-7 compared with flanking 
exons (Li et al, 2012).  High-resolution analysis revealed deletion of an 8.5kb segment 
encompassing AR exons 5-7 in approximately 50% of the cells within this tumor.  
Importantly, LuCaP 86.2 is the tumor model in which the truncated AR v567es variant 
was originally identified (es refers to exon skipping, whereby the splicing machinery 
skips AR exons 5-7, see Figure 1) (Sun et al, 2010).  Although a clear cause-effect has 
not been demonstrated, it would be a logical to predict that the cells in this CRPC tumor 
harboring deletion of AR exons 5-7 are those cells expressing the AR v567es variant.  
The discovery of AR gene rearrangements may also explain why certain tumors favor 
expression of specific species of truncated AR splice variants.  For example, it is 
tempting to hypothesize that ARv567es expression occurs in tumors with genomic 
alterations that impair proper splicing of exons 5-7, whereas AR-V7 overexpression 
arises through genomic rearrangements that promote more efficient splicing of AR exon 
CE3.   
An alternative, non-mutually exclusive, mechanism underlying synthesis of 
truncated AR splice variants could be acute, ADT-induced, changes in regulation of AR 
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splicing.  Such a mechanism was revealed when blockade of full-length AR expression or 
activity in late-passage LNCaP cells or VCaP cells resulted in acute increases in 
truncated AR-V7 protein levels (Hu et al, 2012; Watson et al, 2010).  These acute 
splicing changes were rapidly reversed when expression or activity of full-length AR was 
restored (Watson et al, 2010).  However, although AR-V7 levels were clearly increased 
under these conditions, total levels relative to full-length AR remained low and these 
cells remained dependent on full length androgen signaling (Watson et al, 2010).  
Nevertheless, given the importance of truncated AR variants in CRPC, it will be 
important to elucidate the mechanisms that regulate this plasticity in AR splicing to 
understand the interplay between these mechanisms and AR gene rearrangements in 
CRPC.   
 
1.3.2 Clinical Significance of AR Variants  
An important role for truncated AR variants in CRPC progression is supported by 
several studies demonstrating that metastatic CRPC displays high mRNA and protein 
expression of truncated AR variants compared with hormone-naïve prostatectomy 
specimens (Guo et al, 2009; Hu et al, 2009; Hornberg et al, 2011; Zhang et al, 2011).  
Importantly, western blots of CRPC bone metastases demonstrated that a sub-group of 
CRPC tumors expressed nearly equivalent levels of full-length and truncated AR variants 
(Hornberg et al, 2011).  Moreover, these tissues displayed a higher AR immunostaining 
score, a higher proliferative index, and were associated with shorter survival after surgery 
(2 months vs. 8 months) compared with CRPC tissues that expressed predominantly full-
length AR (Hornberg et al, 2011).  This finding is in-line with another study reporting 
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that prostatectomy specimens displaying above-median AR-V7 expression had a 
decreased probability of PSA progression-free survival (Hu et al, 2009).   
The expression of truncated AR variants in a subset of CRPC may be especially 
relevant in light of new AR-targeted therapies that have recently been approved for 
patients with CRPC.   Abiraterone and enzalutamide both increase overall survival of 
patients with CRPC, but resistance that exists de novo, or resistance that develops during 
therapy is a major limitation for many patients.  In mouse xenograft models, abiraterone 
slowed disease progression, but expression of the truncated AR v567es variant was 
associated with development of resistance (Mostaghel et al, 2011).   Similarly, 
enzalutamide resistance is driven by truncated AR variants in the 22Rv1 and CWR-R1 
cell lines, both of which harbor underlying AR gene rearrangements (Li et al, 2012), and 
treatment of late-passage LNCaP cells or VCaP cells with enzalutamide leads to rapid 
increases in AR-V7 protein expression (Hu et al, 2012). A complete understanding of the 
role of truncated AR variants in driving resistance to abiraterone and enzalutamide in 
patients will require a detailed and integrated analysis of AR gene structure and 
mRNA/protein expression patterns in tissues that display progression during treatment 
with these new agents. 
 
1.3.3 Biochemical properties of Truncated AR Variants   
Nuclear localization of full-length AR is tightly regulated by ligand-binding, and 
AR exists predominantly in the cytoplasm in the absence of androgens.  Classical studies 
have demonstrated that AR nuclear import is supported by a bipartite nuclear localization 
signal located in the hinge domain encoded by AR exons 3 and 4 (Zhou et al, 1994).  
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Therefore, truncated AR variants that do not harbor exon 4-derived sequence would be 
predicted to remain in the cytoplasm.  However, loss of the AR LBD also eliminates the 
AR nuclear export signal.  Recently, it has been shown that the net effect of losing both 
the canonical AR nuclear import and export signals results in constitutive nuclear 
localization of truncated AR variants in the absence of ligand (Chan et al, 2012).  In 
addition, this constitutive nuclear localization of truncated AR variants does not require 
full-length AR.  However, it has been demonstrated that the AR v567es variant can 
facilitate ligand-independent nuclear localization of full-length AR through unclear 
mechanisms (Sun et al, 2010).    
Ectopic expression of truncated AR variants in the androgen dependent LNCaP 
cell line drives androgen independent AR target expression (Dehm et al, 2008; Sun et al, 
2010; Chan et al, 2012) and growth under androgen depleted conditions (Guo et al, 2009; 
Sun et al, 2010; Watson et al, 2010; Chan et al, 2012).  Moreover, androgen-independent 
growth and AR target gene expression in AR splice variant-driven 22Rv1 and CWR-R1 
cell lines are blocked when truncated AR variants are selectively knocked-down.  These 
data indicate that truncated AR variants drive androgen-independent growth by 
supporting ongoing AR transcriptional activity in CRPC cells.  However, it has also been 
shown that truncated AR variants may have unique target gene specificities, perhaps due 
to the influence of variant-derived protein sequence located immediately COOH-terminal 
to the AR DBD.  For example, unique targets have been ascribed to AR-V7, including 
AKT1 (Guo et al, 2009) as well as a set of M-phase genes including UBE2C, which is 
associated with CRPC progression (Hu et al, 2012).  However, some of these apparent 
differences may be due to differences in AR signaling output as opposed to true 
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differences in target gene specificity.  Indeed, UBE2C and other M-phase-associated 
target genes appear to be transcriptional targets of both full-length AR as well as 
truncated AR variants, but these genes display a biphasic pattern with induction at 
proliferative levels of AR signaling and repression at higher, anti-proliferative levels of 
AR signaling (Li et al, 2012).  More recently, gene expression profiling experiments in 
CWR-R1 cells were designed to compare genes responsive to truncated AR variants or 
proliferative doses of DHT.  In this set of experiments, the gene expression profile 
supported by truncated AR variants appeared to be a subset of the broader androgen/AR 
transcriptional program (Li et al, 2012).  In future experiments, it will be important to 
elucidate the sets of genes that are regulated by truncated AR variants in clinical tissues, 
as this may reveal new therapeutic targets downstream of the AR signaling axis.  
 
1.4 Exploiting Genome Alterations to Define PCa Subtypes 
A major goal of cancer genomics is to understand the genomic changes that 
underlie the development and progression of PCa.  This is expected to improve 
prognostic and predictive accuracy for PCa patients.  In particular, classification of 
clinically-relevant subtypes is likely to prove invaluable in a clinical setting by informing 
treatment decisions.  However, the exact criteria of what constitutes a subtype may be 
difficult to define.  Separating tumors based on mutually exclusive genomic aberrations 
or a coordinated set of aberrations that accompany distinguishing physiologies and also 
have bearing on prognostic outcomes and treatment decisions would be ideal.  However, 
even if tumors could be categorized into informative subgroups, PCa is a heterogeneous 
disease and it is possible that more than one subgroup may be present in a given 
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individual.  This is especially relevant in light of the observation that multifocal PCas 
often have different genomic rearrangements occurring between foci (Mehra et al, 2007).  
Additionally, metastatic PCa also appears to have clonal subgroups that respond 
differently to treatments (Ruiz et al, 2011).  Even more daunting is the possibility that 
mutually exclusive genetic events defined as subtypes in the development of PCa may 
not inform treatment decisions or have bearing on prognosis.  Furthermore, genetic 
events that occur as an adaptive response to ADT may be the eminent factors to consider 
when choosing a therapy; this suggests it may be helpful to group cancers based on 
subtypes that result from acquired genomic changes causative of ADT resistance. 
 
1.4.1 PCa Developmental Subtypes 
 TMPRSS2-ERG fusions occur in roughly half of all PCa.  Therefore, one obvious 
PCa subtype is TMPRSS-ERG+/- or, more generally, the presence or absence of any AR-
regulated or otherwise highly-active gene promoter fused to any Ets family protein 
(Rubin et al, 2011).   Recently, genomic studies have provided insights to mutations that 
appear to be important drivers in Ets- tumors. For example, SPOP mutations appear to be 
restricted to primary PCa and CRPC that do not harbor TMPRSS2-ERG fusions (Grasso 
et al, 2012; Barbieri et al, 2012).  Similarly, copy number loss or mutation of CHD1 was 
found to occur in 5.2% of tumors but most frequently in Ets- tumors (Grasso et al, 2012). 
Of note, CHD1 binds to H3K4me histone marks and is commonly deleted in PCa 
contributing to an invasive cell phenotype (Huang et al, 2012).   ETS2, a putative tumor 
suppressor, is also deleted in tumors with the deletion of the 3Mb region between 
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TMPRSS2 and ERG; however, this locus is also mutated at some frequency in 
TMPRSS2-ERG fusion-negative cancers (Grasso et al, 2012).   
 SPINK1 overexpression is another PCa alteration that appears to be mutually 
exclusive with Ets+ cancers (Tomlins et al, 2008) and constitutes a subtype that occurs in 
10% of all PCas.   Notably, SPINK1 shares sequence homology with EGF suggesting that 
it could act as an EGFR agonist.  Moreover, overexpression studies have demonstrated 
that SPINK1 mediates increased invasiveness in vitro (Tomlins et al, 2008), and knock-
down of SPINK1 expression with shRNA or antibodies that neutralize SPINK1 have 
been shown to suppress cellular invasiveness (Ateeq et al, 2011).    Additionally, EGFR 
and SPINK1 suppression has an additive effect in inhibiting cellular invasion in 
SPINK+/Ets- cell line 22RV1 (Ateeq et al, 2011).  
 
1.4.2 PCa Treatment Subtypes 
Genomic changes that occur as a result of ADT may be useful for defining 
treatment-specific PCa subtypes.  Because these would occur later in the natural history 
of PCa progression, these may be constrained or promoted by preceding genomic 
alterations that characterize specific PCa developmental subtypes (Fig. 1-2).  For 
instance, it is unclear whether certain truncated AR variants would be able to interact and 
assemble into a functional complex with the same co-regulator proteins that interact with 
full-length AR.  An example of this is FOXA1, which interacts with full-length AR via 
the DNA binding domain and hinge region (Gao et al, 2003).  Because the AR hinge 
region is missing from most truncated AR variants (with the exception of ARv567es), it 
is possible that FOXA1 pioneer activity may not have the same impact on truncated AR 
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variants as full-length AR.  Similarly, the Ets factor ETV1 interacts with the AR ligand 
binding domain (Shin et al, 2009), which is absent in all truncated AR variants.  
Interestingly, many of the studies involving ectopic expression of truncated AR variants 
have been performed in the LNCaP cell line, which displays overexpression of ETV1, 
including a study which found that full length AR was required for androgen-independent 
function of truncated AR variants (Watson et al, 2010).  In contrast, DAXX, which is 
involved in cellular differentiation and proliferation, regulates AR activity by binding to 
the AR NTD (Lin et al, 2004).  Therefore, DAXX may be able to interact with and 
regulate activity of truncated AR variants in a manner similar to full-length AR.  
Interestingly, SPOP has been shown to bind to and regulate DAXX (Kwon et al, 2006), 
suggesting a potential interplay between SPOP and the AR in PCa.  In addition SPOP has 
also been shown to regulate SRC-3, an important AR co-regulator overexpressed in 
CRPC (Li C et al, 2011; Wang et al, 2005).   
Changes to the necessity or nature of AR signaling inductive to CPRC such as 
bypass pathways or changes to the AR itself such as mutations to change ligand 
specificity, amplifications to sensitize AR to ligand, and rearrangements that induce 
truncated AR splice variants may occur regardless of developmental subtypes and 
potentially be the dominant factor with regards to ADT response (Saraon et al, 2009; 
Pienta et al, 2006).  For example, AR amplification can occur regardless of TMPRSS2-
ERG fusion or other developmental subtype status (Bismar et al, 2012).   However, it 
may be significant that AR gene amplification is associated with copy number gain of 
NCOA2 and a higher overall incidence of genomic copy number alterations (Friedlander 
et al, 2012).  AR gene amplification can also increase AR levels and sensitivity to 
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residual DHT levels and lead to bicalutamide resistance (Chen et al, 2004).  
Alternatively, inappropriately expressed biosynthetic enzymes that enable intratumoral 
synthesis of androgens, reviewed extensively elsewhere (Cai et al, 2011), are likely to 
drive ongoing AR signaling without structural changes to the AR gene locus.  In these 
cases, it is anticipated that tumors harboring AR gene amplifications or altered expression 
of DHT biosynthetic enzymes would respond to therapy with abiraterone or 
enzalutamide.  Indeed, enzalutamide was developed with the goal of addressing the 
challenge of treating CRPC driven by AR protein overexpression.   
In contrast to amplification- or mutation-based alterations in full-length AR 
activity, evidence suggest that cancers driven by truncated AR variants may not require 
full length AR and would thus be resistant to treatments targeting the LBD or androgen 
synthesis (Barbieri et al 2012; Hu et al, 2012; Li et al, 2012).  This highlights the need to 
develop drugs that target the AR NTD or DBD, which are encoded by the first three 
exons of the AR gene.  One such drug is EPI-001, which has been shown to bind the AR 
NTD and prevent transcriptional activity of full-length AR by blocking interactions with 
important AR coactivators (Andersen et al, 2010).  Additionally, changes in growth 
factor signaling axes such as EGFR or IGF1, reviewed elsewhere (Saraon et al, 2011), 
may activate AR signaling in the absence of ligand or bypass AR signaling altogether by 
activating mitogenic signaling pathways and render tumors resistant to antiandrogen 
therapies.   Importantly, AR gene amplification events and AR gene rearrangement 
events may not be mutually exclusive, as AR gene copy number imbalances have been 
observed in CRPC xenografts and clinical metastases displaying overall increases in AR 
copy number (Li et al, 2011; Li et al, 2012). 
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1.5 Future Perspectives  
Recent advances in technology and increased sophistication have illuminated 
complex changes that occur in PCa and possible patterns that can be exploited 
therapeutically.  However, AR alterations that drive ADT resistance, such as point 
mutations, copy number increases, and intragenic rearrangements have not been linked to 
other contextual alterations in the PCa genome.  Whole genome sequencing on CRPC 
metastases is anticipated to yield insights into the context and patterns of resistance to the 
expanding repertoire of drug options for ADT.  
The complexity of AR regulation necessitates the development of rigorous cell 
models able to parse the effects of intragenic AR rearrangements.  Genome editing 
technology has afforded researchers with the tools to create isogenic models of disease 
that recapitulate genomic events associated with a phenotype, allowing for greater control 
of unknown contextual effects.  In the work presented here, AR is modified to recreate 
AR-V associated genomic lesions in this fashion.    
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1.6 Figures 
Figure 1-1  Genome rearrangements associated with AR variants 
 
 A schematic of the AR gene structure is shown with cryptic exons (not to scale).  
Genomic regions involved in AR gene rearrangements associated with enhanced 
expression of truncated AR variants are indicated with dashed lines (above).  The 
domain structure of full length AR and truncated AR variants with included exons 
are indicated (below).  Regular AR exons are in gray, cryptic exons in white.  
NH2-terminal domain (NTD), DNA-Binding Domain (DBD), Ligand Binding 
Domain (LBD).  
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 Figure 1-2 Prostate cancer subtypes associated with development and progression  
 
 The relationship between PCa developmental subtypes is depicted on top.  The 
relationship between developmental subtypes and treatment subtypes is largely 
unknown but subsequent changes to AR in response to ADT can be organized into 
the hierarchical categories depicted on the bottom. 
 
Reprinted with permission from: 
Nyquist MD, Dhem SM (2013) Interplay between genomic alterations and androgen 
receptor signaling during prostate cancer development and progression. Hormones 
and Cancer 4(2):61-9 
Copyright © Springer Publishing 
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CHAPTER 2: TALEN-Engineered AR Gene Rearrangements Reveal Endocrine 
Uncoupling of Androgen Receptor in Prostate Cancer 
Androgen receptor (AR) target genes direct development and survival of the prostate 
epithelial lineage, including prostate cancer (PCa).  Therefore, endocrine therapies that 
inhibit the AR ligand-binding domain (LBD) are effective in PCa.  AR transcriptional 
reactivation is central to resistance, as evidenced by efficacy of AR retargeting in 
castration resistant PCa (CRPC) with next-generation endocrine therapies abiraterone and 
enzalutamide.  However, resistance to abiraterone and enzalutamide limits efficacy for 
most men, and PCa remains the second leading cause of male cancer deaths.  Here we 
show that AR gene rearrangements in CRPC tissues underlie a completely androgen-
independent, yet AR-dependent, resistance mechanism.   We discovered intragenic AR 
gene rearrangements in CRPC tissues, which we modeled using transcription activator-
like effector nuclease (TALEN) mediated genome engineering.  This revealed that these 
AR gene rearrangements blocked full-length AR synthesis, but promoted expression of 
truncated AR variant proteins (AR-Vs) lacking the AR LBD.  Further, AR-Vs maintained 
constitutive activity of the AR transcriptional program and a CRPC growth phenotype 
independent of full-length AR or androgens.  These data demonstrate that AR gene 
rearrangements are a novel resistance mechanism by which AR transcriptional activity 
can be uncoupled from endocrine regulation in CRPC.  
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2.1 Introduction 
Prostate cancer (PCa) is the most commonly diagnosed cancer in men and is the 
second leading cause of male cancer mortalities (Siegel et al, 2013).  The androgen 
receptor (AR) is a steroid receptor transcription factor that drives prostate development 
and homeostasis and is crucial for PCa growth and survival (Garraway and Sellers, 
2006).  The AR gene is located on the X chromosome, and encodes a modular protein 
consisting of three major domains: exon 1 encodes the NH2-terminal domain (NTD), 
exons 2 and 3 encode a central DNA binding domain (DBD), and exons 4-8 encode the 
COOH-terminal ligand binding domain (LBD).  The NTD is responsible for the majority 
of AR transcriptional activity, but this activity is suppressed by the LBD unless AR is 
bound to testosterone or dihydrotestosterone (DHT) (Callewaert et al, 2006; Christiaens 
et al, 2002; Dehm et al, 2007; He et al, 2004; Jenster et al, 1995).  Currently, advanced or 
metastatic PCa is treated by systemic inhibition of androgen synthesis and antiandrogens 
that bind to the AR LBD (Ryan et al, 2011).  Despite robust responses to these endocrine 
therapies, castration resistant prostate cancer (CRPC) inevitably develops concurrent with 
AR transcriptional reactivation (Attard et al, 2011; Chen et al, 2009).   
Identification of AR overexpression and high tissue androgen levels as 
mechanisms driving AR reactivation in a subset of CRPC tumors led to the clinical 
development and recent approval of abiraterone and enzalutamide as new endocrine 
targeting therapies for treatment of CRPC (Attard et al, 2008; Chen et al, 2004; de Bono 
et al, 2011; Montgomery et al, 2008; Scher et al, 2012; Titus et al, 2005; Tran et al, 
2009).  However, despite the success of these drugs at improving overall survival, 
primary and secondary resistance is a major limitation for most patients. Point mutations 
24 
 
in the AR LBD have been implicated in resistance to enzalutamide in CRPC cell line 
models (Balbas et al, 2013).  Similarly, increased intratumoral steroidogenesis has been 
observed in CRPC xenograft models that have developed resistance to abiraterone 
(Mostaghel et al, 2011).  These findings support continued efforts to block the 
ligand:LBD interaction in order to achieve durable AR inhibition. 
An additional occurrence in CRPC is the production of COOH-terminally 
truncated AR splice variants (AR-Vs).  Diverse AR-Vs have been reported, all of which 
contain the AR NTD and DBD, but lack the AR LBD (Dehm and Tindall, 2011).  
Functional studies have demonstrated that AR-Vs can function as constitutively nuclear, 
constitutively active transcription factors (Chan et al, 2012).  AR-Vs have been shown to 
be enriched in CRPC, and track with poor clinical outcomes (Guo et al, 2009; Hornberg 
et al, 2011l; Hu et al, 2009; Zhang et al, 2011).  Recently, AR gene rearrangements were 
identified in CRPC cell lines that display high-level expression of AR-Vs (Li Y et al 
2011; Li et al, 2012).  However, AR-Vs are co-expressed with full-length AR in these 
cell lines, which has made it challenging to pinpoint the precise contributions of AR-Vs 
to endocrine therapy resistance and a CRPC phenotype.  Here, we report intragenic AR 
gene rearrangements in tissues from clinical CRPC metastases that completely block full-
length AR synthesis.  We modeled these intragenic rearrangements using TALEN 
genome engineering (Cermak, et al, 2011), and found that these rearrangements underlie 
exclusive expression of truncated AR-Vs and uncoupling of the AR transcriptional 
program from endocrine regulation.  Overall, this study represents the first report of a 
completely androgen-independent, AR-V-dependent resistance mechanism, and 
establishes the clinical relevance and a functional context of AR-Vs in CRPC.  
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2.2 Results 
2.2.1 AR-V associated intragenic AR rearrangements in clinical CRPC tissue.   
LuCaP 86.2 is a PCa xenograft established from a CRPC bladder metastasis 
resected from a 79 year-old patient (Kumar et al, 2011). This xenograft expresses full-
length AR encoded by exons 1-8, but also expresses an AR-V protein thought to be an 
alternative splicing product arising from skipping of AR exons 5-7 (ARv567es) (Sun et 
al, 2010).  However, since AR is on the X chromosome, discovery of an 8.5kb deletion of 
AR exons 5-7 in LuCaP 86.2 tissue indicates that ARv567es and full-length AR 
expression may be mutually exclusive and restricted to distinct cell populations (Li et al, 
2012).  In line with this, fluorescence in situ hybridization (FISH) and 
immunofluorescence staining demonstrated that all LuCaP 86.2 cells harbored a single 
AR gene copy and stained positive with an antibody specific for the AR NTD (Fig. 2-1 
A,B).  However, high-resolution AR copy number analysis using multiplex ligation-
dependent probe amplification (MLPA) assay revealed that the AR exon 5-7 segment 
encoding the AR LBD was deleted in approximately half of these cells (Fig. 2-1 C).  The 
relative ratios of deletion-positive and deletion-negative cells were stable during long-
term propagation in castrated mice, as were expression ratios of full-length AR and 
ARv567es (Fig. 2-1 C,D).  Together, these data demonstrate the existence of at least two 
stable CRPC subclones in heterogeneous LuCaP 86.2 tissue, one of which harbors an 
intragenic deletion of AR exons 5-7.  To establish the clinical relevance of this finding, 
we used a PCR-based method and verified heterogeneity for cells with the 8.5kb deletion 
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breakpoint in both the LuCaP 86.2 xenograft and in CRPC cells procured by laser capture 
microdissection of archival patient tissue (Fig. 2-2 A and Fig. 2-3 A-C).   
Interestingly, a different PCa xenograft established from CRPC abdominal 
ascites, LuCaP 136, also expresses ARv567es mRNA and protein (Kumar et al, 2011; 
Sun et al, 2010).  Whole exome re-sequencing of LuCaP 136 genomic DNA has been 
performed (Kumar et al, 2011), but this did not provide an obvious basis for ARv567es 
expression, and intragenic deletion of AR exons 5-7 was not detected using PCR (Fig. 2-
3 D).  Therefore, we re-sequenced the 183kb AR gene in LuCaP 136 genomic DNA via 
hybrid capture followed by Illumina-based massively parallel paired-end sequencing.  
This analysis revealed a copy-neutral 8.7 kb inversion encompassing AR exons 5-7 (Fig. 
2-2 B, Fig. 2-4 C).  In contrast to heterogeneous AR expression in LuCaP 86.2 (Fig. 2-2 
C,D and Fig. 2-5), early-passage LuCaP 136 tissue displayed exclusive expression of 
ARv567es mRNA (Fig. 2-2 C) and protein (Fig. 2-2 D), which was consistent with very 
few cells harboring a normal AR allele (Fig. 2-4 D).  Although there was no archival 
patient material corresponding to LuCaP 136, discovery of this intragenic AR inversion 
was made in tissue that had been propagated for only two passages in non-castrate male 
mice.  Later passages of LuCaP 136, which were serially-propagated in non-castrate male 
mice, displayed coordinate loss of cells with this AR exon 5-7 inversion allele and AR 
v567es protein expression (Fig. 2-6).   
 
2.2.2 Targeting nucleases recreate ARv567es-associated genome rearrangements.   
To study the functional significance of these novel AR gene rearrangements in 
CRPC tissues, we pursued genome engineering in a monoclonal sub-line isolated from 
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the CWR-R1 PCa cell line (Gregory et al, 2001), termed R1-AD1 (Li Y et al, 2013).  R1-
AD1 cells harbor one intact AR gene copy, express full-length AR, and display growth 
stimulation in response to androgens and growth suppression in response to AR 
antagonists including enzalutamide (Li Y et al, 2013).  We constructed two TALEN pairs 
(Cermak et al, 2011; Bogdanove and Voytas, 2011; Miller et al, 2011), one pair targeting 
AR intron 4 (AR-int4) and one pair targeting AR intron 7 (AR-int7) (Fig. 2-7 A and Fig. 
2-8 A).  Site-specific double-strand (ds) DNA cleavage by AR-int4 and AR-int7 TALENs 
was confirmed by assays that measure mutations introduced by TALEN cleavage and 
imprecise DNA repair (Fig. 2-8 B,C).  When both AR-int4 and AR-int7 TALENs were 
co-expressed, deletion or inversion events involving the AR exon 5-7 segment were 
observed (Fig. 2-8 D-F).  Using limiting dilution plating and PCR screening, we isolated 
and expanded two clonal cell lines derived from R1-AD1, one with a deletion (R1-D567) 
and one with an inversion (R1-I567) of AR exons 5-7 (Fig. 2-7 B).  AR exon copy 
number analysis by MLPA demonstrated that R1-AD1 and R1-I567 cells harbored one 
copy of each AR exon, whereas exons 5-7 had been deleted in R1-D567 cells (Fig. 2-7 
C).  Furthermore, the genome-engineered R1-I567 and R1-D567 cell lines displayed 
exclusive expression of ARv567es variant mRNA (Figs. 2-7 D,E and Fig. 2-9) and 
protein (Fig. 2-7 F).  These data confirm that the rearrangements involving the AR exons 
5-7 segment that were discovered in CRPC tissues are causative events underlying 
expression of ARv567es. 
 
2.2.3 ARv567es drives androgen independence in genome engineered cell lines.   
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Since deletion or inversion of AR exons 5-7 eliminates the AR LBD, cells 
harboring these rearrangements should have a growth advantage over androgen-
dependent PCa cells under conditions where full-length AR activity is inhibited.  To test 
this, we performed competitive growth assays wherein R1-AD1 cells were transfected 
with AR-int4 and AR-int7 TALENs and then cultured for 20 days in the presence of 
androgens (FBS or CSS + 1nM DHT), or under conditions of full-length AR inhibition 
(CSS or CSS + 1uM enzalutamide).  Quantitative PCR was used to measure the 
enrichment of rare cell populations harboring alleles with targeted inversions or deletions 
relative to all cells.  Maintenance under conditions of full-length AR inhibition resulted in 
the relative enrichment of deletion- and inversion-positive cells.  In contrast, under 
androgen rich conditions, deletion- and inversion-positive cells displayed relative de-
enrichment (Fig. 2-10 A).   
One explanation for these findings could be that deletion or inversion of AR 
exons 5-7 functionally inactivates AR, causing an AR bypass mechanism of CRPC 
(Miyamoto et al, 2012).   This would be consistent with the notion that full-length AR is 
required for AR-dependent CRPC progression, even if AR-Vs are expressed (Watson et 
al, 2010).  An alternative explanation could be that ARv567es, which retains the 
transcriptionally active AR NTD/DBD core (Chan et al, 2012) (Fig. 2-2 C) may be able 
to drive a completely ligand-independent, yet AR-dependent CRPC phenotype.  To test 
this, we performed reporter assays with an AR-responsive MMTV promoter.   In parental 
R1-AD1 cells, MMTV displayed robust androgen induction, which was blocked by 
knock-down of full-length AR (Fig. 2-10 B).  Conversely, in R1-D567 and R1-I567 cells, 
MMTV displayed constitutively high basal activity, but no androgen induction.  
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However, high basal MMTV activity in R1-I567 and R1-D567 cells was blocked by 
knock down of ARv567es (Fig. 2-10 B).   These data demonstrate that ARv567es is a 
constitutively active transcription factor in R1-I567 and R1-D567 cells.  
We next tested whether constitutive ARv567es transcriptional activity could drive 
androgen-independent growth in R1-I567 and R1-D567 cells.  DHT enhanced the growth 
of parental R1-AD1 cells, which was inhibited by knock-down of full-length AR (Fig. 2-
10 C,D).  Conversely, R1-I567 and R1-D567 displayed robust androgen-independent 
growth, which was inhibited by knock-down of ARv567es (Fig. 2-10 C,D).  These data 
demonstrate that these AR gene rearrangements underlie a shift from a growth profile 
that is dependent on androgens and full-length AR to a growth profile that is driven by 
constitutive ARv567es activity.  
 
2.2.4 ARv567es effects a constitutive form of the androgen/AR transcriptional 
program.  
To determine whether ARv567es was functioning globally as a constitutive 
transcriptional regulator, we performed gene expression microarray analysis of parental 
R1-AD1 cells and R1-D567 cells.  First, we identified genes that were differentially 
expressed between full-length AR “on” (1nM DHT) and “off” (vehicle control) states in 
R1-AD1 cells.  Next, we identified genes that were differentially expressed between 
ARv567es “on” (control siRNA) and “off” (siRNA targeting AR exon 1) states in R1-
D567 cells.  Overall, the majority of genes that displayed differential expression between 
ARv567es “on” and “off” states in R1-D567 also displayed a similar directional change 
between the AR “on” and “off” states in parental R1-AD1 cells (Fig. 2-11 A).  This was 
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confirmed for several shared target genes (FKBP5, FASN, and LIMA1) by direct qRT-
PCR analysis (Fig. 2-12). In line with this, knowledge-based Ingenuity Pathway Analysis 
(IPA) revealed that the only significant multi-gene networks displaying differential 
expression in parental R1-AD1 cells or R1-D567 cells had AR as the prominent central 
hubs (Figs. 2-13).  Together, these findings indicate that ARv567es supports constitutive 
activation of a transcriptional program very similar to the program regulated by full-
length AR.  To test this more rigorously, we used Gene Set Enrichment Analysis (GSEA) 
(Subramanian et al, 2005).  Genes that were induced or repressed 1.2-fold by DHT in 
parental R1-AD1 cells were positively or negatively enriched in the R1-D567 gene 
expression dataset, respectively (Fig. 2-11 B).  When we tested the reciprocal 
relationship, identical results were observed: genes that were induced or repressed 1.2-
fold by ARv567es in R1-D567 were positively or negatively enriched in the R1-AD1 
gene expression dataset, respectively (Fig. 2-11 C and Tables 2-2, 2-3).  Based on these 
data, we conclude that AR gene rearrangements are a CRPC resistance mechanism 
whereby the AR transcriptional program can be uncoupled from endocrine regulation.  
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2.3 Discussion 
ARv567es as well as other AR-Vs are expressed in CRPC, but the mechanisms 
underlying this expression, and their functional significance, has been poorly understood 
(Dehm and Tindall, 2011).  In previous studies, we have shown that intragenic AR 
rearrangements occur in CRPC cell lines where truncated AR-Vs were first discovered, 
explaining high-level expression of AR-Vs concurrent with full-length AR in these 
models (Li Y et al, 2011; Li et al 2012).  For example, the 22Rv1 cell line harbors a 35kb 
tandem duplication encompassing AR exon 3, and this intragenic duplication is 
associated with high-level mRNA and protein expression of the truncated AR-V7 (also 
referred to as AR3 and AR 1/2/3/CE3) and AR 1/2/3/2b (also referred to as AR-V4 and 
AR5) variants (Chan et al, 2012; Guo et al, 2009; Hu et al, 2009; Dehm et al, 2008).  The 
CRPC CWR-R1 cell line harbors a population of cells with a 48kb intragenic deletion of 
AR intron 1, and these deletion-positive cells display high-level expression of AR-V7 
and resistance to enzalutamide (Guo et al, 2009; Hu et al, 2009; Li et al, 2012; Li et al, 
2013).  However, these findings are associative and have not established a clear cause-
effect relationship between AR gene rearrangements and functional AR-V expression.  
The data presented here demonstrate that CRPC LuCaP 86.2 and LuCaP 136 tissues also 
harbor intragenic rearrangements, associated with expression of the ARv567es variant.  
However, this study provides an important breakthrough because it establishes a causal 
relationship between specific genome rearrangements discovered in CPRC tissues and 
functionally significant AR-V expression.  By modeling these specific intragenic AR 
gene rearrangements using a novel TALEN genome engineering approach, we have 
demonstrated that these genomic events underlie a true androgen independent phenotype 
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through a mechanism of switching AR expression from full-length AR to ARv567es.  
Furthermore, we have established ARv567es as the active protein driving this androgen-
independent phenotype by effecting a broad androgen/AR transcriptional program. 
A rearrangement-dependent mechanism of AR-V expression in CRPC tissues 
contrasts with the observation that AR-V7 expression increases acutely in VCaP and late-
passage LNCaP cells in response to endocrine targeting therapy (Hu et al, 2012) 
supporting growth of VCaP cells when full-length AR is inhibited (Liu et al, 2013).  This 
plasticity in AR-V expression could be attributable to a negative feedback loop, wherein 
transcription of the AR gene is actively repressed by androgen-bound full-length AR via 
recruitment of lysine specific demethylase 1 (LSD1) (Cai et al, 2011).  Based on this 
mechanism, AR inhibition would lead to transcriptional de-repression and increased 
expression of both full-length AR as well as AR-V7.  However, unlike AR gene 
rearrangements, this mechanism does not appear to affect relative expression ratios, and 
AR-V7 remains a minor constituent of overall AR expression (Hu et al, 2012; Liu et al, 
2013).   
Tumor heterogeneity and subclonal architecture is not apparent when lysates from 
cell lines or tissues are assessed for mRNA or protein expression.  A frequent finding in 
CRPC cell lines and tissues, including LuCaP 86.2 and LuCaP 136, is concurrent 
expression of AR-Vs along with full-length AR (Guo et al, 2009; Hornberg et al, 2011; 
Hu et al, 2009; Zhang et al, 2011; Sun et al, 2010).  Modeling this co-expression by 
transfecting AR-Vs in LNCaP cells led to the conclusions that full-length AR and 
ARv567es can physically interact (Sun et al, 2010),  that ARv567es facilitates nuclear 
localization and transcriptional activation of full-length AR under castrate conditions 
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(Sun et al, 2010), that full-length AR is required for ARv567es to drive features of the 
CRPC phenotype (Sun et al, 2010; Watson et al, 2010), and that antiandrogens such as 
enzalutamide can inhibit full-length AR and thereby inhibit any effects of AR-Vs 
(Watson et al, 2010).  Our data highlights the importance of understanding the subclonal 
architecture of CRPC cell lines and tumor tissue when assessing AR-V expression and 
function.  Indeed, there have been conflicting reports about the association of AR-V 
expression levels with clinical disease progression (Guo et al, 2009; Hornberg et al, 2011; 
Hu et al, 2009; Zhang et al, 2011; Zhao et al, 2012), and our data suggests that this could 
be due to the variable degree to which heterogeneous CRPC tumors are enriched for AR-
V expressing cells.   
The majority of men progressing on abiraterone and enzalutamide display rising 
serum levels of the AR-regulated PSA gene, indicating these tumors remain AR-driven 
(de Bono et al, 2011; Scher et al, 2012; Ryan et al, 2012).  This has spurred ongoing 
development of additional endocrine therapies that act on the AR LBD (Balbas et al; 
Clegg et al, 2012; DeVore and Scott, 2012).  Importantly, the AR gene rearrangements 
discovered and modeled in this study provide a complete genetic block of full-length AR 
and represent a previously-unanticipated endocrine uncoupling escape mechanism.  
Identification of AR-Vs as the ultimate functional outcome of this mechanism highlights 
a need for development of new therapies targeted to the AR-V core, which is composed 
of the transcriptionally active AR NTD and AR DBD (Anderson et al, 2010; Dehm and 
Tindall, 2007).  In addition, this work highlights an opportunity to develop AR gene 
rearrangements as stable biomarkers of resistance to endocrine targeting therapies for 
prostate cancer.   
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2.4 Methods 
Tissues.  Genomic DNA samples from the LuCaP series of PCa xenografts and de-
identified clinical CRPCa tissue were obtained from the University of Washington 
Prostate Cancer Biorepository, which was developed and managed by one of the co-
authors (R.L.V.) and has been described in previous publications (Zhang et al, 2011; 
Kumar et al, 2011; Sun et al, 2010).   
 
Cell lines.  The LNCaP (#CRL-1740) cell line was obtained from American Type 
Culture Collection ATCC (Manassas, VA) and CWR-R1 cells were provided by Dr. 
Elizabeth Wilson (UNC Chapel Hill, NC).  The R1-AD1 cell line (CWR-R1, androgen-
dependent 1, referred to as “deletion-negative clone 1” in the original publication) (Li et 
al, 2012) is a subline derived from single-cell cloning of the CWR-R1 cell line.  R1-AD1 
cells are androgen responsive and contain a structurally normal copy of the AR gene (Li 
et al, 2012; Li et al, 2013).  Cells were maintained in in RPMI 1640 medium 
supplemented with 10% FBS in 5% CO2 incubator at 37OC. 
 
MMTV-luciferase reporter assays.  Promoter-reporter assays with an MMTV-
Luciferase reporter were performed as previously described (Dehm et al, 2008). 
 
Cell growth assays.  Cell growth was monitored by crystal violet staining as previously 
described (Li Y et al, 2011).  For 20-day growth enrichment assays, cells were 
electroporated with either a CMV-GFP expression vector and pBluescript stuffer vector 
or equal masses of all four TALENs.  Transfected cells were plated on 6-well tissue 
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culture plates and grown to confluence.  Confluent cells were trypsinized and re-seeded 
on 6-well tissue culture plates in RPMI 1640 medium supplemented with  10% FBS,  
10% CSS, 10% CSS + 1uM enzalutamide (Selleck Chemicals), or 10% CSS + 1nM DHT 
(Sigma) .  Cells were cultured for 20 days under these conditions with trypsinization and 
re-seeding when cells became confluent.  At the end of 20 days genomic DNA was 
harvested for analysis by quantitative PCR. 
 
Western blots.  Western blots were performed as previously described (Li Y et al, 2011)  
using antibodies specific for the AR NTD (N-20, Santa Cruz Biotechnology) and ERK2 
(D-2, Santa Cruz Biotechnology).  
 
Generation of R1-D567 and R1-I567 cell lines.  To isolate clonal cell lines with 
targeted intragenic deletion or inversion of the AR exon 5-7 segment, cells were 
electroporated with TALENs, plated and allowed to recover for 3 days.  Transfected cells 
were transferred to tissue culture dishes at limiting dilution.  When colonies became 
visible (~3wks to 1month), cells were picked, trypsinized, and plated into 96-well plates.  
Clones were expanded and split into two separate plates, one of which was used for PCR 
screening.  Genomic DNA was extracted using a QuickExtract kit (Catalog#: QE0905T, 
Epicentre-Illumina) according to the manufacturer’s protocol.  Genomic DNA was then 
used for PCR screening with rearrangement-specific primers (Table 2-1).  Positive clones 
were expanded.  Clonal purity of R1-D567 and R1-I567 cell lines were determined by 
secondary PCR screening, and met criteria of positive PCR signals with rearrangement-
specific primers and negative PCR signals with wild-type specific primers (Table 2-1). 
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 Multiplex ligation-dependent probe amplification (MLPA).  MLPA assays were 
performed as described previously (Li et al, 2012).   
 
Gene expression microarray analysis.  Gene expression microarray analysis with 
Illumina Human HT-12 V4 Beadchips was performed as described previously (Li et al, 
2013).  Samples used in analysis were in biological triplicates.  R1-D567 cells were 
electroporated with either siCNTL or siAR-exon1 (Table 2-1).  R1-AD1 cells were 
electroporated with siCNTL.  Electroporated cells were plated in RPMI 1640 medium 
supplemented with 10% CSS.  After 48h, cells were switched to serum free RPMI-1640 
medium supplemented with 1nM DHT or 0.1% (v/v) ethanol (vehicle control) for 24 
hours. Gene lists were derived from genes displaying an expression increase or decrease 
of ≥1.2 fold (p = ≤ 0.05 with Benjamini-Hochberg FDR correction) in R1-AD1 1nM 
DHT vs. EtOH and R1-D567 siCNTL vs. siAR-exon1.  Heat maps were generated using 
Cluster 3.0 software (http://bonsai.hgc.jp/~mdehoon/software/cluster/software.htm).  
Data are available through NCBI’s Gene Expression Omnibus (GSE49196). 
  
Gene set enrichment analysis (GSEA).  Lists of differentially-expressed genes were 
analyzed for enrichment in normalized gene expression datasets using GSEA analysis 
software v2.0.10 (http://www.broadinstitute.org/gsea/index.jsp).  Normalized gene 
expression data was ranked using the Signal2Noise metric and GSEA was performed 
against 1000 random gene set permutations.  All other analysis options were left at the 
default setting. 
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 Florescent In-Situ Hybridization (FISH).  FISH was performed by the Cytogenetics 
Shared Resources Laboratory at the Masonic Cancer Center.  BAC probe RP11-807F19 
(ChrX:66714000-66908813) was labeled with Orange - 552 dUTP (Enzo Life Science) 
using a nick translation kit (Abbott Molecular) as per the manufacturer’s protocol.  
Precipitated probe fragments were dried and resuspended in 50% formamide 
hybridization buffer and mixed with a Spectrum Green-labeled commercial probe for the 
centromere of chromosome X (Abbott Molecular). Frozen cryosection slides of LuCaP 
86.2 tissue were thawed and pretreated in a sequence of 2xSSC, ethanol, and acetone in 
preparation for hybridization with the FISH probes.  The probe/hybridization buffer mix 
was applied to pretreated tissue slides. Slides were placed in a Thermobrite (Abbott 
Molecular) denaturation/hybridization chamber, denatured for 5 minutes at 75°C, then 
incubated overnight at 37°C.  Slides were washed in a 2xSSC solution at 72° for 15 
seconds, and counterstained with 4',6-diamidino-2-phenylindole (DAPI) stain.  Slides 
were visualized on an Olympus BX61 microscope workstation (Applied Spectral 
Imaging, Vista, CA) using DAPI, FITC and Texas Red filter sets.  Images were captured 
using an interferometer-based CCD cooled camera (ASI) and BandView ASI software. 
 
Immunofluorescence (IF).  LuCaP 86.2 tissues that had been passaged in intact (s36n9 
and s36n8-1; s and n = number of passages in SCID and NSG mice, respectively) or 
castrated (s7n2-2 and s7n2-3) mice were frozen in optimal temperature cutting (OTC) 
media and 6 micron sections were cut onto slides.  Tissues were fixed by cold acetone for 
5 min, dried at room temperature 10 min, then rehydrated in 1X phosphate buffered 
38 
 
saline (PBS) at room temperature for 10 min.  Samples were blocked for 1 hour at room 
temperature with blocking buffer (0.2% Tween-20 and 2% BSA in 1X PBS) containing 
5% normal goat serum (Sigma #G 9023).  AR N-20 primary antibody (Santa Cruz) was 
applied overnight at 4oC at a 1:200 dilution in blocking buffer.  Cells were washed 3 
times for 5 minutes each in a washing buffer containing 0.2% Tween-20 in 1XPBS.  The 
secondary antibody, goat anti-rabbit Alexa Fluor 488 F(ab')2 Fragment of Goat Anti-
Rabbit IgG (H+L) Antibody (Life Technologies), was applied for 1 h at room 
temperature at a 1:500 dilution in blocking buffer.  Slides were washed twice for 5 
minutes each in washing buffer and then incubated for 15 minutes of 1ug/mL DAPI 
followed by a final wash of 5 minutes in 1X PBS.  Cells were then mounted with 
Vectashield mounting media (Vector Laboratories) and images were captured with a 
fluorescent microscope (Nikon Eclipse TS100) equipped with a 20X objective. 
 
Next-generation paired-end re-sequencing of the 183kb AR gene.  Genomic DNA 
from LuCaP 136 xenograft tumor tissue was subjected to hybrid capture with a custom 
SureSelect bait library (Agilent) and sequenced at 6000X depth with 2X100bp settings on 
an Illumina HiSeq 2000 as described(Li Y et al, 2012).  Briefly, raw sequence data from 
HiSeq 2000 was de-multiplexed and filtered using CASAVA 1.8.  FASTQ formatted 
reads were inspected using fastQC (Babraham Bioinformatics Institute).  Filtered reads 
were trimmed (from an initial length of 2 x 100 bp to 2 x 85 bp, removing sequence from 
the 3′ end) to remove low-quality ends using the FASTQ trimmer tool in Galaxy, then 
mapped to the hg19 build of the reference genome using Burrows-Wheeler Alignment 
(BWA)(2).  Briefly, for BWA alignment, the seed size was 20 (“-l 20”).  Up to two 
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differences within the seed (“-k 2”), up to 4 differences in each read end (“-n 4”), and up 
to 1 gap opening in the alignment (“-o 1”) were allowed. In the alignment pairing phase, 
the maximal expected insert size (“-a”) was set to be 500.  Up to 10 million possible 
mapping locations (“-o 10000000”) were also allowed. Output BAM files from BWA 
were sorted, followed by removal of potential PCR duplicates using Picard tools 
(http://picard.sourceforge.net/).  Discordantly-mapped read pairs and soft-clip reads were 
collected and used to identify structural variations via LUMPY 
(https://github.com/arq5x/lumpy-sv) with parameters: -mw 3, -tt 1e-3, back_distance:20, 
weight:1, min_non_overlap:85, discordant_z:7, back_distance:20, mean:227, stdev:73. 
 
Transient transfections.  Cells were transfected with siRNAs and/or plasmid vectors by 
electroporation as described previously(Dehm et al, 2008).  Briefly, 2-3X106 cells were 
re-suspended in 350 uL of media and mixed with 50 uL of TE buffer containing 
120pmoles of siRNA and/or 12ug of DNA.  Cell/siRNA/DNA mixes were added to a 
4mm gap-width cuvette and subjected to 2X 275 volt pulses of 100ms interval/pulse. 
Cells were allowed to recover 15 minutes at room temperature before plating.  Control 
siRNA was purchased from Dharmacon (siCNTL siGENOME Non-Targeting siRNA #1, 
Cat# D-001210-01-50).  AR-targeted siRNAs had the following sequences: siAR-Exon1, 
sense: 5’-CAAGGGAGGUUACACCAAA, antisense: 5’-
UUUGGUGUAACCUCCCUUG; siAR-Exon7 sense: 5’-
GGAACUCGAUCGUAUCAUU, antisense: 5’-AAUGAUACGAUCGAGUUCC.   
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RT-PCR and quantitative RT-PCR.  RNA was isolated and converted to cDNA as 
described previously(Li Y et al, 2011).  cDNA was used for PCR reactions with Exon 4 
fwd and Exon 8 rev primers (Table 2-1) using Taq DNA polymerase (Qiagen, catalog 
#201205) according to the manufacturer’s protocol.  For quantitative RT-PCR assays, 
cDNA was used for quantitative PCR reactions with primers specific for FKBP5, 
LIMA1, FASN, and GAPDH (Table 2-1) using a BioRad iCycler and PerfeCTa Sybr 
Green FastMix (Quanta Biosciences, 95072-250) according to the manufacturer’s 
protocol.   
   
TALEN nuclease construction.  Design and construction of expression vectors for 
TALENs was carried out as previously described (Cermack et al, 2011).  Briefly, TALEN 
pair target sites were chosen so that each TALEN contained 15 repeat variable di-residue 
(RVD) modules with a 14-15 base pair spacer in between each TALEN target site.  The 
TALEN RVD modules were assembled from a cloning library (Addgene, Golden Gate 
TALEN and TAL Effector Kit 2.0, #1000000024) and Golden Gate cloning method.  
RVD modules were assembled into two fusion vectors (FusA and FusB) per TALEN, one 
containing the first 10 RVD modules and the second containing four RVD modules.  The 
final TALENs were constructed through a single Golden Gate cloning reaction with the 
FusA and FusB vectors, the last half RVD module, and the mammalian expression vector 
backbone pC-GoldyTALEN (Addgene:#38143)(Carlsonet al, 2012). 
 
Genomic DNA PCR and Surveyor (Cel 1) nuclease assays. PCR for detection of 
targeted deletions or inversions in R1-AD1 cells and for Cel 1 assays were performed 
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using Phusion-HF Polymerase Kit with HF buffer (Catalog#: M0530S, New England 
Biolabs) according to the manufacturer’s protocol.   PCR primers are listed in Table S1.  
For assays with Surveyor (Cel 1) nuclease, genomic PCR products were separated on 1% 
agarose gels and the bands were excised and purified using a QIAquick Gel Extraction kit 
(Catalog#: 28706 Qiagen) according to the manufacturer’s protocol.  A 400ng aliquot of 
the purified PCR product was digested using Surveyor Mutation Detection Kit 
(Catalog#:706025 Transgenomic) according to the manufacturer’s protocol.  Digests 
were analyzed on 2% agarose gels. 
 
Genomic DNA PCR.  Genomic DNA was isolated from tissues and cell lines using a 
Nucleospin tissue kit (Catalog#: 740952, Machery-Nagel) according to recommended 
protocol.  PCR with LuCaP86.2 and LuCaP 136 genomic DNA was performed using Taq 
DNA polymerase (Qiagen, catalog #201205) according to the manufacturer’s protocol.  
Primers for PCR detection of the LuCaP 86.2 deletion junction, the LuCaP 86.2 5’ 
inversion junction, the LuCaP 86.2 3’ inversion junction, and wild-type AR locus 
controls are listed in Table S1.   
 
Quantitative genomic PCR.  Quantitative PCR with genomic DNA from 20-day growth 
enrichment assays was carried out using a LightCycler 480 II (Roche) and Lightcycler 
480 SYBR Green I Master Mix (Catalog 04707516001, Roche) according to the 
manufacturer’s protocol.  Primers used to detect inversion and deletion junctions are 
listed in Table S1.  Threshold cycle of amplification (Ct) values derived using inversion 
and deletion-specific primers were normalized against Ct values derived from primers 
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targeting a control region in AR intron 2 (Table 2-1).   Data were transformed using the 
formula 2-ddCt with the relative level of inversions and deletions at Day 0 arbitrarily set to 
1.  Quantitative PCR on LuCaP136 genomic DNA was performed using qLuCaP 136 F1 
and qLuCaP 136 R1 to amplify inversion junctions and qLuCaP F1 and qAR normal R1 
was used to specifically amplify wild type AR.  All samples were normalized to an 
unrelated locus in AR intron 1 using primers qAR intron1 F and qAR intron 1R.  
Quantitative PCR was performed using the Perfecta SYBR Green Fastmix according to 
recommended protocol (Quanta Biosciences, Catalog#:95071-012) (primers are listed in 
Table 2-1).      
 
Cloning and sequencing of PCR and RT-PCR products.  AR cDNA products were 
cloned using the TA-TOPO Cloning Kit (Catalog#:45-0641, Invitrogen) according to the 
manufacturer’s protocol.  Genomic PCR products were cloned using the CloneJet PCR 
cloning kit (Catalog#: K1231 Thermo Scientific) according to the manufacturer’s 
protocol.  All cloned plasmids were sequenced by Sanger sequencing with a universal T7 
primer.   
 
Microarray sample preparation.  Cells were harvested using Trizol (Life Technologies, 
catalog#:15596-026) according to the manufacturer’s protocol.  Total RNA was then 
column purified using an RNeasy Mini Kit (Qiagen, Catalog#: 74104) and 2 ug was 
submitted to the University of Minnesota Biomedical Genomics Center for Illumina 
Direct Hybridization array analysis (Illumina, San Diego, CA). RNA quality control was 
performed using a NanoDrop 8000 spectrophotometer (Thermo Fisher 
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Scientific,Waltham,MA) and Caliper LabChip GX (Caliper Life 
Sciences,Hopkinton,MA).  Total RNA was converted to amplified biotinylated, antisense 
cRNA using the Illumina TotalPrep-96 RNA Amplification Kit (Life Technologies, 
Carlsbad, CA), and 150 ng of biotin-labeled cRNA was hybridized onto Illumina 
HumanHT-12 v4 Expression Beadchips (Illumina, San Diego, CA) using the HumanHT-
12 v4 Expression BeadChip Kit (Illumina, San Diego, CA). Hybridized Beadchips were 
scanned with an Illumina iScan.  Raw intensity data was extracted from iScan scan image 
files (Illumina) using GenomeStudio software (Illumina), log2 transformed, and then 
imported to Partek Genomics Suite 6.6 (Partek Inc., St. Louis, MO).  Using Partek GS, 
raw intensity data was quantile normalized and differential gene expression was 
determined by one-way analysis of variance (ANOVA) using default settings within the 
Gene Expression Workflow.   
 
Ingenuity Pathways Analysis (IPA).  Lists of differentially-expressed genes were 
analyzed using Ingenuity Pathway Analysis (IPA, version 8.5, Ingenuity Systems, 
http://www.ingenuity.com, Core 8.5, Ingenuity Analysis), a commercial application that 
infers the relationship between the gene set and known pathways. We used default 
settings, wherein ‘Ingenuity Knowledge Base (Genes Only)’ was the reference set, and 
both direct and indirect relationships were considered to identify sub-networks enriched 
with the selected genes. 
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 2.5 Figures 
Figure 2-1. LuCaP 86.2 tissue is heterogeneous for cells with an intact AR gene and cells 
harboring deletion of AR exons 5-7. 
 
 
45 
 
Figure 2-1.  (A)  Representative image of LuCaP 86.2 tissue subjected to FISH with a 
probe specific for the AR gene (Spectrum Red signal) and a probe specific for the X 
centromere (Spectrum Green signal).  Evaluation of 200 cells revealed that 193 cells 
(96.5%) had one red signal and one green signal, 3 (1.5%) cells had one red signal and no 
green signal, and four cells (2%) had no red signal and one green signal.  (B) 
Immunofluorescence was performed using an antibody specific for the AR NTD (Alexa 
Fluor 488 signal) and nuclei were stained with DAPI.  Representative fluorescence 
microscopy images are shown for three color channels (Alexa Fluor 488, DAPI, and 
merged Alexa Fluor 488/DAPI)  (C) MLPA genomic copy number analysis in LuCaP 
86.2 tissues that had been propagated in intact (s36n9 and s36n8-1; s and n = number of 
passages in SCID and NSG mice, respectively) or castrated (s7n2-2 and s7n2-3) mice.  
(D)  Western blot for the AR NTD or ERK-2 (loading control) in LuCaP 86.2 tissue 
propagated in intact or castrated mice. Contributions: (A,D) Oseth LA, Betsy Hirsh B  
(D) Li Y. 
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Figure 2-2. AR gene rearrangements linked to AR-V expression in CRPC.   
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Figure 2-2.  (A) PCR analysis of an 8.5kb deletion of AR exons 5-7 in genomic DNA 
isolated from the LuCaP 86.2 xenograft model, CRPC bladder metastasis used to 
establish LuCaP 86.2 (Met), or adjacent normal bladder (NB).  H20, water as no template 
control. (B) An 8.7 kb inversion of AR exons 5-7 in passage 2 of the LuCaP 136 
xenograft, which was established from CRPC cells in abdominal ascites fluid.  mh, 
microhomology. (C) RT-PCR analysis of AR mRNA in LNCaP cells, LuCaP 86.2 tissue, 
or LuCaP 136 tissue.  Exon organization and relationship with functional protein domains 
for full length AR (AR-FL) and the ARv567es splice variant is shown.   Heteroduplex 
formation in LuCaP 86.2 PCR products was confirmed in Fig. 2-5.  NTD, NH2-terminal 
domain; DBD, DNA binding domain; LBD, ligand binding domain. (D) Western blot for 
the AR NTD or ERK-2 (loading control) in LNCaP cells, LuCaP 86.2 tissue, and LuCaP 
136 tissue. Contributions: (A,B) Dehm SM, Li Y, Hwang TH (C,D) Li Y. 
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Figure 2-3.  LuCaP 86.2 xenograft tissue and CRPC bladder metastasis used to establish 
LuCaP 86.2 xenograft are heterogeneous for cells harboring the LuCaP 86.2 AR 
intragenic deletion signature. 
 
Figure 2-3.  (A) Schematic of PCR primer design for detection of wild-type or exon 5-7 
deletion AR gene architectures. (B) PCR testing for the presence of cells harboring 
normal AR gene architecture in genomic DNA from CRPC bladder metastasis, adjacent 
normal bladder, or LuCaP 86.2 tumor tissue. (C) Sanger sequence trace of the AR 
intragenic deletion signature in a CRPC bladder metastasis used to establish LuCaP 86.2, 
and alignment match with the LuCaP 86.2 deletion signature.  (D) PCR testing for 
deletion of AR exons 5-7 in genomic DNA from LuCaP 86.2 and LuCaP 136 tumor 
tissue.  For this experiment, a forward primer binding within AR exon 4 and a reverse 
primer binding within AR exon 8 were used. Contributions: (A- D) Li Y. 
49 
 
Figure 2-4. LuCaP 136 xenograft tissue is highly enriched for cells harboring intragenic 
inversion of AR exons 5-7.   
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Figure 2-4.  (A) Schematic of PCR primer design for detection of AR intragenic 
inversion in LuCaP 136.  (B) PCR testing for the 5’ (top) and 3’ (bottom) break fusion 
junctions caused by intragenic inversion in genomic DNA from BPH-1 cells, LuCaP 86.2 
tissue, and LuCaP 136 tissue.  (C) MLPA genomic copy number analysis of the AR gene 
in genomic DNA from LuCaP 136 tissue.   (D) Relative percentage of cells with a wild-
type AR gene architecture in LuCaP 136 tumor tissue was assessed using quantitative 
PCR with primers specific for a wild-type, non-inverted AR gene architecture.  Threshold 
cycle of amplification (Ct) values were calibrated relative to a control region in the AR 
locus (intron 1) using the relative threshold cycle of amplification method (2-ddCt).  Data 
are shown relative to BPH-1 cells, which were arbitrarily set to 100% based on the 
assumption that this cell line is homogeneous for cells harboring wild-type AR gene 
architecture in the target region. Contributions: (A- D) Li Y. 
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Figure 2-5. A heteroduplex PCR artifact following RT-PCR analysis of AR mRNA 
expression in the heterogeneous LuCaP 86.2 xenograft.   
 
 
Figure 2-5. (A) Representative agarose gel electrophoresis of LuCaP 86.2 RT-PCR 
products derived using exon 4 forward/exon 8 reverse primer pairs.  (B) Individual bands 
were excised, subjected to column purification, and (C) analyzed by agarose gel 
electrophoresis in separate lanes.  The purified heteroduplex band was able to re-
constitute all three products observed on the original agarose gel. Contributions: (A- C) 
Li Y. 
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Figure 2-6. Loss of inversion-positive cells from the LuCaP 136 xenograft following 
serial passage under non-castrate conditions.   
 
Fig. 2-6.  (A) Origin of different passages of LuCaP 136 tumor tissue used for analysis of 
AR gene structure and expression patterns.  (B)  PCR testing for the 5’ break fusion 
junction caused by intragenic inversion of AR exons 5-7 in genomic DNA from three 
different passages of LuCaP 136.  (C) PCR testing for the presence of cells harboring 
normal AR gene architecture in genomic DNA from three different passages of LuCaP 
136.  (D) Western blot for the AR NTD or ERK-2 (loading control) in whole cell extracts 
from three different passages of LuCaP 136. Contributions: (A- D) Li Y. 
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Figure 2-7.  Engineered inversion or deletion of AR exons 5-7 using TALENs 
recapitulates tissue-associated AR splicing events.   
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Figure 2-7.  (A) Genome engineering strategy for creating isogenic cell lines harboring 
inversion or deletion of AR exons 5-7.  TALEN pairs targeted to AR intron 4 (AR-int4) 
or AR intron 7 (AR-int7) are depicted as red arrowheads. (B) Representative Sanger 
sequencing trace of the deletion junction from the genome-engineered R1-D567 cell line, 
and the 5’ inversion junction from the genome-engineered R1-I567 cell line. (C) MLPA 
genomic copy number analysis in parental R1-AD1 cells, and genome-engineered R1-
I567 and R1-D567 cells. (D) RT-PCR analysis of AR mRNA in parental R1-AD1 cells, 
and genome-engineered R1-I567 and R1-D567 cells.  (E) Representative Sanger 
sequencing trace of the AR exon 4/8 splice junction in ARv567es RT-PCR products from 
panel D.  (F) Western blot for the AR NTD or ERK-2 (loading control) in parental R1-
AD1 cells, and genome-engineered R1-I567 and R1-D567 cells. Contributions: (C) Hirsh 
B, Oseth LA. 
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Figure 2-8.  Evaluating AR-targeted TALENs for site-specific dsDNA cleavage activity.   
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Figure 2-8.  (A) Schematic of TALEN expression vectors (top). TALEN binding sites in 
AR introns 4 and 7 (underlined).  Sites of targeted dsDNA cleavage are within the spacer 
region (italicized) (middle). Repeat-variable di-residue (RVD) module sequence of 
TALEN DNA binding domains (bottom). (B) Schematic of genomic regions surrounding 
TALEN target sites (black arrows).  Locations of PCR primer binding sites and predicted 
PCR fragment lengths are indicated.  (C) Cel1 assay, measuring indels (insertion or 
deletions) caused by dsDNA break repair through error prone non-homologous end 
joining (NHEJ), of genomic DNA from LNCaP cells transfected with individual 
TALENs or a GFP control vector.  (D) PCR testing for deletion events in genomic DNA 
from LNCaP cells co-transfected with AR-Int4 and AR-Int7 TALENs.  (E) Deletion 
junction sequences of 7 randomly picked cloned PCR products derived from PCR 
reactions in (D).  (F)  PCR testing for inversion events in genomic DNA from LNCaP 
cells transfected as in (D). 
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Figure 2-9.  cDNA sequences of ARv567es RT-PCR products from R1-I567 and R1-
D567 cells.   
 
Figure 2-9.  cDNA sequence derived from exon 4 is highlighted in yellow, and cDNA 
sequence derived from exon 8 is highlighted in green.  Novel amino acids derived from 
the frameshift caused by AR exon 8 splicing to AR exon 4 are indicated by red letters.  
Asterisks denote ARv567es stop codon. 
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Figure 2-10.  ARv567es expression induced by AR gene rearrangements drives an 
androgen-independent prostate cancer phenotype.   
 
Figure 2-10.  (A) Relative enrichment of cells with AR intragenic deletion or inversion 
events induced by transfecting R1-AD1 cells with AR-int4 and AR-int7 TALENs.  Cells 
were growth to confluence after transfection, and then re-plated on Day 0 under 
androgen-rich (FBS or CSS + 1nM DHT) or castrate (CSS or CSS + 1uM 
enzalutamide/Enz) conditions.  On Day 20, plates were tested for enrichment of cells 
with AR deletion or inversion alleles relative to all AR alleles (intron 2) by quantitative 
PCR (N = 6).  p-values were calculated using the two-tailed t-test. CSS, charcoal-stripped 
serum; FBS, fetal bovine serum; DHT, dihydrotestosterone. (error bars = SD).  (B) 
Promoter-reporter assays following co-transfection with an AR-responsive MMTV-
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luciferase reporter and small interference RNAs targeted to AR exon 7 or AR exon 1.  
Transfected cells were treated 24h with 1nM DHT as indicated.  Results are the mean (N 
= 3).  p-values were calculated using the two-tailed t-test.   The data are shown for one 
triplicate experiment, which is representative of three independent biological replicates, 
each of which reached statistical significance (p < 0.05) (error bars = SD).  (C) Western 
blots for the AR NTD or ERK-2 (loading control) in R1-D567 and parental R1-AD1 cells 
transfected with siRNA targeting AR exon 1.  (D) Growth assays of parental R1-AD1 
cells and genome-engineered R1-I567 and R1-D567 cells transfected as in panel C (N = 
4).  p-values shown are the largest of any comparison between bracketed groups and were 
calculated using the two-tailed t-test.  The data are shown for one quadruplicate 
experiment, which is representative of two independent biological replicates, each of 
which reached statistical significance (p<0.05). (error bars = SD)   
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Figure 2-11. ARv567es induced by AR gene rearrangements drives constitutive, 
androgen-independent expression of the AR transcriptional program.   
 
Figure 2-11. (A) Heat map of microarray data showing genes differentially expressed in 
R1-D567 cells transfected with control siRNA (siCNTL) vs. siAR targeting AR exon1 
(ARv567es transcriptome), and responses of these same genes to 1nM DHT in parental 
R1-AD1 cells. Data represent mean centered expression changes in log2 scale for 3 
independent biological replicates.   (B) GSEA interrogating R1-D567 gene expression 
data for enrichment of genes that were either up regulated 1.2 fold (top in red) or down 
regulated 1.2 fold (bottom in blue) in R1-AD1 cells in response to treatment with 1nM 
DHT.  False discovery rate (FDR) q-values are shown for each plot.   (C) GSEA as in 
panel B interrogating R1-AD1 gene expression data for enrichment of genes that were 
either up regulated 1.2 fold (top in red) or down regulated 1.2 fold (bottom in blue) in 
R1-D567 cells transfected with control siRNA (siCNTL) vs. siAR targeting AR exon1. 
61 
 
Figure 2-12.  Quantitative RT-PCR analysis of representative genes displaying 
coordinate regulation by androgen/AR and ARv567es.  
 
Figure 2-12.  Expression of the indicated genes was assessed following androgen-
treatment of R1-AD1 cells, or siRNA-mediated knock-down of ARv567es in R1-D567 
and R1-I567es cells.  Results are the mean (N=3).  p-values shown were calculated using 
the two-tailed t-test (Error bars = SD).  The data are shown for one triplicate experiment, 
which are representative of two independent biological replicates, each of which reached 
statistical significance (p<0.05).   
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Figure 2-13.  Ingenuity Pathways Analysis of differentially expressed genes from 
microarray analyses.   
 
Figure 2-13.  (A) Ingenuity Pathways Analysis was performed using genes displaying 
differential regulation between the ARv567es “on” state (control siRNA) and ARv567es 
“off” state (siRNA targeted to AR exon 1) in R1-D567 cells. (B) Ingenuity Pathways 
Analysis was performed using genes displaying differential regulation between the AR 
“on” state (1nM DHT) and AR “off” state (ethanol vehicle control) state in R1-AD1 
cells. Contributions: Hwang TH. 
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2.6 Tables 
Table 2-1. Primers used in chapter 2 
q-PCR primers for R1-AD1 genomic DNA  
qpcr-INT2 F 5'-TCCCATTTTCAGGCCTCTTA 
qpcr-INT2 R 5'-GCTTAAGCCCTGGGTGGT 
qpcr-INT4 F 5'-TCTGTTTCTCCAGAACAGCCTA 
qpcr-INT7 R 5'-GAAATGGTCTCCATGGAGTC 
qpcr-INT7 F 5'-GAGAGAGAGAGAGATGGAGTGC 
  LuCaP 86.2 deletion PCR  
qdel F2 5’-TAGGGTTGCAGCTACTCTTTCC 
qdel R3  5’-TGCTTAGCACTCAAACCCAGTA 
nor F **same as qdel F2 
nor R2 5’-TGTGTGTTAGAGAGAGACAGCGA 
  LuCaP 136 Inversion PCR  
136inv int4+ 5'-ATTTGGAGTGGGTGAGTAGACTGG 
136inv int7+ 5'-TGCTTTTATCAGGGAGAACAGCC 
136inv int4- 5'-AGCTCTCTGACTCAGACTTC 
136inv int7- 5'-GTGAATGTGAAGGCACATGG 
  LuCaP 136 quantitative Inversion PCR  
qLuCaP 136 F1 5'-CCACTTGCCTTGCCTAGAAG 
qLuCaP 136 R1 5'-GGGTGGAGGAGTTGAGAACA 
qAR normal R1 5'-CAAAGAAAGGCCAGTTTGGA 
qAR intron1 F 5’-TGGATGGATAGCTACTCCGG 
qAR intron1 R 5’-TTTACCCTGCTGAGCTGTCC 
  AR RT-PCR 
 EXON4 F 5'-GCAGCAAAGATTTCCAAACTGG 
EXON8 R 5'-TGGGTGTGGAAATAGATGGG 
  R1-AD1 screening and cel1 PCRs 
Int4 F 5'-GCAGCAAAGATTTCCAAACTGG 
Int4 R 5'-CAAGCAAATTGTCCATACTGATGC 
Int7 F 5'-GCTTTATCAGGGAGAACAGCCTG 
Int7 R 5'-CCTCTGATTTTTGGTCTTTCAGCC 
  Sequencing PCRs 
 T7 5'-GTAATACGACTCACTATAGGG 
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qRT-PCRs 
 qpcr-GAPDH F 5'-GAAGGTGAAGGTCGGAGTC 
qpcr-GAPDH R 5'-GAAGATGGTGATGGGATTTC 
qpcr-FKBP5 F 5'-AGGAGGGAAGAGTCCCAGTG 
qpcr-FKBP5 R 5'-TGGGAAGCTACTGGTTTTGC 
FASN F1 5'-CTGAAGCGTGGCCTGAAG 
FASN F2 5'-CTTCCTCACCTCCACTGAGC 
LIMA1 R1 5'-TTTTGCTTGCCCATAGATCC 
APIP F1 5'-ACTGGGACTGGAGGAGGAAT 
APIP R1 5'-ATCACTGCACCTGCTCCTCT 
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Table 2-2. GSEA statistics 
 
 
Name  of Gene Set ES NES 
NOM 
p-val 
FDR 
q-val 
FWER 
p-val 
RANK 
AT 
MAX  
R1-
AD1_DHT_RESPONS
E_1.2_FOLD_UP 0.975728 3.733761 0 0 0 964  
R1-
D567_ARV_1.2_FOL
D_UP 0.732285 2.648226 0 0 0 2475  
        Enriched in R1-AD1 
with EtOH 
       
Name  of Gene Set ES NES 
NOM 
p-val 
FDR q-
val 
FWER 
p-val 
RANK 
AT MAX  
R1-
AD1_DHT_RESPONS
E_1.2_FOLD_DN -0.97838 -3.96718 0 0 0 649  
R1-
D567_ARV_1.2_FOL
D_DN -0.74185 -2.86152 0 0 0 2539  
       
 
Enriched in R1-D567 
siCNTL 
      
 
Name  of Gene Set ES NES 
NOM 
p-val 
FDR q-
val 
FWER 
p-val 
RANK 
AT MAX  
R1-
D567_ARV_1.2_FOL
D_UP 0.961824 3.444299 0 0 0 1410  
R1-
AD1_DHT_RESPONS
E_1.2_FOLD_UP 0.66122 2.495106 0 0 0 3822  
       
 
Enriched in R1-D567 
siAR2 
      
 
Name  of Gene Set ES NES 
NOM 
p-val 
FDR q-
val 
FWER 
p-val 
RANK 
AT MAX  
 R1-
D567_ARV_1.2_FOL
D_DN -0.96871 -3.73744 0 0 0 1065  
R1-
AD1_DHT_RESPONS
E_1.2_FOLD_DN -0.72273 -2.98245 0 0 0 3473  
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Table 2-3. Gene lists used in GSEA 
R1-
D567_ARV_1.2_fol
d_UP 
R1-
D567_ARV_1.2_fol
d_DN 
R1-
AD1_DHT_Response_1.2_
fold_UP 
R1-
AD1_DHT_Respons
e_1.2_fold_DN 
DAGLB ANXA1 C13ORF15 DKK1 
ERRFI1 IGSF9 ATP1A1 ETV5 
ARHGAP23 PARP10 MME KIAA1199 
ATP1A1 PLEKHB1 TOMM34 FER1L3 
MBOAT2 C1ORF116 MBOAT2 RAB7B 
CYBA MB UGT2B7 ANXA1 
CYP27B1 CYFIP2 NT5DC3 AGR2 
GNPDA1 LPAR5 PRR15L ID1 
PLEKHA6 HS.370359 HOMER2 IGSF9 
CEBPD ZMIZ2 HERC5 MYOF 
HS.538962 ABCA1 CHN2 FOXC1 
BTG2 N4BP2L2 UGT2B11 KIAA1671 
FASN ALDH3A2 PYGB ETV4 
TSPYL2 SIPA1L2 ADAMTS9 KIAA0040 
GSTO1 LOC100132901 SOCS2 FGFBP1 
ACOT7 ID2 UGT2B28 FAM108C1 
TSPAN18 HOXC13 PLEKHA6 SPRY2 
OSBP ZNF323 CEBPD ENC1 
RDH11 CYP3A5 HS.370359 OCIAD2 
LOC100133185 TSPAN8 FASN SPRED2 
TINP1 FAM134B TSPYL2 HS.434957 
ACSS2 FLJ22184 TIPARP MAP7 
LOC653375 LRP10 S100P C20ORF118 
BTBD7 TP53INP1 LOC93622 LPAR5 
HSPB3 VCAN LOC729768 FAIM2 
GLB1 C9ORF152 MVD INO80C 
AR C1ORF115 ERN1 VWF 
TTLL12 EPCAM MFSD2 DUSP6 
PIGP CLDN3 C16ORF79 PHCA 
APOD SSPO PACSIN1 TM4SF1 
FLJ25404 GSN CMAS AKR1B10 
LMNA OXTR APIP PHLDA1 
LRRC8A SCNN1A ETNK2 CMBL 
DAPL1 XBP1 TAP1 EMP1 
67 
 
TABLE 2-3 cont.    
R1-
D567_ARV_1.2_fol
d_UP 
R1-
D567_ARV_1.2_fol
d_DN 
R1-
AD1_DHT_Response_1.2_
fold_UP 
R1-
AD1_DHT_Respons
e_1.2_fold_DN 
KDELR2 LOC653108 LOC284422 LRRC49 
RAG1AP1 DACH1 TTLL12 CD58 
TUBA3D FYCO1 PDIA5 RBM47 
EHD4 LOC645381 EPHX2 ALDH3A2 
SAFB2 AARS TMEM38B CPNE4 
LIPH HS.155736 SHRM CEACAM1 
DUOX1 CXADR LRRC8A AGPAT9 
NSA2 SERPINI1 EXOSC5 CLIC1 
PMM1 ASS1 C19ORF48 PRSS23 
BOLA3 ADNP TNS3 ARHGEF3 
SRP68 NRCAM KDELR2 SIPA1L2 
LOC100128196 ALDH1L2 TUBA3D ID2 
HSPB6 CBLN2 SGK1 ALDH1A3 
HS.564874 ABR SAFB2 TGFB3 
ODF2 BRI3 COPS8 HOXC13 
TSC2 FAM84B PECI CAMP 
FBXO18 HS.28456 FAM174B VAV3 
CD82 ANKRD50 BIN1 SOX7 
C5ORF25 PCMTD1 PMM1 STK3 
LGI2 CEBPG SRP68 LOC100134170 
IQCK LOC728533 CUX2 TSPAN8 
ZBTB16 GAS6 TSPAN33 C1ORF127 
DGUOK STX3 BBS10 MFSD6 
PALLD CDH18 NUBP2 ADAMTS1 
AZI1 ZNF615 TSC2 PCDHB2 
IPO7 ATP9A TBC1D4 CCDC3 
CDK5 DMAP1 SLC4A7 BCL3 
ISCA1 HIST1H3H FLJ90086 PHLDA2 
SSSCA1 ASAP2 RABAC1 C9ORF152 
ABHD6 MBP AFF3 TMTC1 
CDC42 GSTA4 KLK4 C1ORF115 
CD99L2 AVIL RALY CREB3L4 
RASD1 ZNF524 FADS1 FUT4 
LOC100132658 HLX FKBP5 AMHR2 
TKTL1 RPS6KA2 ANXA2 CTSL2 
CCDC6 WASL LDHB GSN 
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TABLE 2-3 cont.    
R1-
D567_ARV_1.2_fol
d_UP 
R1-
D567_ARV_1.2_fol
d_DN 
R1-
AD1_DHT_Response_1.2_
fold_UP 
R1-
AD1_DHT_Respons
e_1.2_fold_DN 
ELMOD1 HS.492187 SSR3 SHROOM2 
AP1S2 SDC4 HS.571245 CLCF1 
PDLIM7 FAM102A RNF150 PTPN13 
ABCG4 GSTA3 LIG1 OXTR 
SS18 ZDHHC1 FZD9 NDE1 
JPH1 ZNF467 BEST2 LOC653108 
FAM96B CD47 TMEM214 NCAM2 
SH2B3 ZFAND1 PDLIM1 PLEKHG4 
NLRX1 GPNMB CDK5RAP3 RIN2 
DUSP3 LOC653506 GADD45G TNFRSF19 
CAMKV PCDH19 EAF2 TXNDC5 
FABP6 CPNE3 CYB5R3 ZBTB33 
SNAI2 TGFBR3 SLC6A3 HS.25318 
SIX4 HS.559604 ABHD6 DNAJC12 
SNORA67 PIK4CA WDR41 HS.155736 
UNC5A MACROD1 GAA CXADR 
NOC2L RALYL NUCB1 CARM1 
LAPTM4B CDC42SE2 ABCC4 ZMYND15 
GAGE12J ZBTB42 CECR6 SLC12A2 
DKK3 AFF2 HS.19339 ITGA2 
 
DNAJB9 LONRF1 CRABP2 
 
P4HTM BTBD11 SLC20A2 
 
ARHGAP24 MRFAP1 DNAJC22 
 
KAT2B C6ORF81 ACOX2 
 
AKTIP FHDC1 ASS1 
 
ZSCAN16 GMPPB LAD1 
 
RWDD2A ARSA CXORF26 
 
SIGIRR RHOB LIMA1 
 
MAL2 GMPPA MPZL2 
 
HS.335413 LACTB CYTH2 
 
SLC1A5 KLHDC4 ABR 
 
RNF149 CADPS2 FAM84B 
 
SLC23A3 PHACTR3 LYPD6B 
 
HS.352818 NTHL1 TMSB4X 
 
SARS CYB5A SCGB2A2 
 
ADM2 EEF2K SYTL2 
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TABLE 2-3 cont.    
R1-
D567_ARV_1.2_fol
d_UP 
R1-
D567_ARV_1.2_fol
d_DN 
R1-
AD1_DHT_Response_1.2_
fold_UP 
R1-
AD1_DHT_Respons
e_1.2_fold_DN 
 
C11ORF54 GHR PROM2 
 
FOXN2 STK39 CCDC50 
 
HS.444683 SOD2 LEF1 
 
NAGK LOC387856 TNFRSF21 
 
ILDR1 TXNDC16 ID3 
 
GOLSYN SAMM50 ANKRD57 
 
TMEM125 IMPA2 CAPRIN2 
 
KLHDC8B VPS26B IPO8 
 
RP1L1 FBXL15 TMBIM4 
 
PPP1R9A MRPL2 DLX3 
 
WDR20 TRAP1 JMJD1C 
  
NEURL1B SCGB1D2 
  
FLJ10324 LMCD1 
  
SNX25 ACYP2 
  
HTRA2 GSTA4 
  
PLOD1 GPR177 
  
PACS1 NFKBIZ 
  
PIAS1 COBLL1 
  
RNF103 VIPR1 
  
SLC25A1 NAB1 
   
SDC4 
   
C6ORF117 
   
C9ORF3 
   
ANKRD22 
   
GJB4 
   
FRMD6 
   
GSTA3 
   
C15ORF52 
   
AHR 
   
LOC730413 
   
CYP4X1 
   
TFAP2A 
   
NRP1 
   
TLE1 
   
PNPLA7 
   
ZNF428 
70 
 
   TABLE 2-3 cont. 
   
R1-
AD1_DHT_Respons
e_1.2_fold_DN 
   
ZCCHC12 
   
SERPINE2 
   
KIAA1324 
   
CCDC102A 
   
BBS2 
   
CD44 
   
FAM149B1 
   
PLEKHA9 
   
SLC44A2 
   
C12ORF26 
   
PLEKHH2 
   
MARCKS 
   
GPX2 
   
FES 
   
CDH3 
   
SNCG 
   
IGSF3 
   
SELENBP1 
   
FABP5 
   
MIDN 
   
CNKSR3 
   
METAP2 
   
WDR72 
   
SOX2 
   
EFHD1 
   
C1QL4 
   
HOXB5 
   
ATP2C1 
   
DIP2B 
   
IRX5 
   
C10ORF32 
   
CASK 
   
GNRHR 
   
LPHN2 
   
GPR56 
   
RBM22 
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TABLE 2-3 cont. 
   
R1-
AD1_DHT_Respons
e_1.2_fold_DN 
   
PTP4A2 
   
RNY5 
   LOC642956 
   LITAF 
   
LOC100128098 
   
IFNGR2 
   
SYNGR4 
   
SETMAR 
   
FLJ40125 
   
B9D2 
 
 
Reprinted with permission from: 
Nyquist MD, Li Y, Hwang TH, et al (2013) TALEN-engineered AR gene  
rearrangements reveal endocrine uncoupling of androgen receptor in prostate 
cancer. Proc Natl Acad Sci U S A 110(43):17492-7 
Copyright © National Academy of Sciences of the United States of America 
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CHAPTER 3: TALEN-mediated modeling of AR gene rearrangements associated 
with AR-V7 production in human prostate cancer cell lines. 
Prostate cancer is the most frequently diagnosed male cancer.  Therapies that 
target the androgen receptor (AR) are highly effective for management of aggressive 
disease.  However, development of therapeutic resistance and emergence of the lethal 
castration-resistant prostate cancer phenotype is frequent.  One mechanism of therapeutic 
resistance is the acquired expression of constitutively active AR splice variants (AR-Vs).  
However, the mechanism by which they are expressed remains poorly understood.  
Overexpression of splice variant AR-V7 has been associated with intragenic AR 
rearrangements but it is not known whether specific rearrangements are causative of 
overexpression.  In this study, we induced sequence-specific nuclease-mediated gene 
modifications to model intragenic AR rearrangements that are associated with AR-V7 
over-expression in castration-resistant prostate cancer (CRPC) cell lines 22Rv1, and 
CWR-R1.  Our data demonstrate that duplication of a ~35kb region surrounding exon 3, 
as in 22Rv1, can enhance AR-V7 expression.  However, low levels of AR-V7 persisted 
even after the duplication was reversed.  This suggests that there are multiple, non-
mutually exclusive modes of AR-V7 overexpression.      
 
3.1 Introduction 
Prostate cancer (PCa) is the most frequently diagnosed cancer in men and the 
second highest cause of male cancer deaths (Siegel et al, 2013).  Prostate tissue 
homeostasis is maintained by the transcriptional activity of the AR.  And AR continues to 
function as a master regulator in prostate cancer (Garraway and Sellers, 2006).  AR 
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consists of an amino-terminal transcriptional domain (NTD), a DNA binding domain 
(DBD), and a carboxyl-terminal ligand binding domain (LBD).  When not bound to 
ligand, AR remains in an inactive state in the cytoplasm.  Upon binding to 
dihydrotestosterone (DHT), AR translocates to the nucleus where it dimerizes and 
activates transcription (Callewaert et al, 2006; Christiaens et al, 2002; He et al, 2004; 
Jenster et al, 1995).  Accordingly, when PCa progresses to an aggressive, metastatic 
disease, the primary treatment is androgen deprivation therapy (ADT), which is achieved 
by reducing the availability of androgens (castration) or use of chemical antagonists that 
bind to the AR LBD (Ryan and Tindall 2011).  Inevitably, PCa develops resistance to 
these therapies and progresses to castration resistant prostate cancer (CRPC) within 
several years.   
ADT resistance is often caused by reactivation of AR signaling though myriad 
alterations in AR regulation.  The best defined AR reactivation mechanisms include point 
mutations or amplification of the AR gene, or intratumoral androgen biosynthesis (Shafi 
et al, 2013; Chang et al, 2013).  These alterations have been re-retargeted successfully in 
the clinic with the anti-androgen enzalutamide as well as the androgen biosynthesis 
inhibitor abiraterone acetate.  However, the overall survival benefit achieved by these AR 
re-targeting strategies is limited to a few months (Scher et al, 2012; de Bono et al, 2011).  
An additional AR reactivation mechanism that occurs in CRPC is expression of AR 
splice variants (AR-Vs) (Dehm and Tindall, 2011).   AR-Vs, such as AR-V7 and AR-
V567es, contain the NTD and DBD of the AR protein, but are prematurely truncated 
prior to the ligand binding domain, obviating the requirement for DHT.  In this way, 
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variants effect a constitutive AR signaling program and are inert to LBD targeted 
therapies (Li Y et al, 2013; Nyquist and Dehm, 2012).       
Understanding the modes of AR-V expression is important for precision 
medicine, prognostic biomarker research, and drug development.  One study found that 
splice factors U2AF65 and ASF/SF2 are required for splicing of AR cryptic exon 3 
(CE3), the exon in AR-V7 (Liu LL et al, 2013).  However, the study did not address how 
these splicing factors are involved in the inappropriate expression of AR-V7.  Intragenic 
AR rearrangements have been found in cell lines where high levels of AR-V expression 
drive castration resistant growth (Li Y et al, 2011; Li Y et al, 2012; Li Y et al, 2013). 
    One example of this scenario is the CRPC 22Rv1 cell line, which is 
characterized by a ~35kb intragenic tandem duplication in the AR gene and high-level 
expression of several discrete AR-V species, including AR-V7 (Li Y et al, 2011).  
Similarly, CWR-R1 has been shown to be a heterogeneous cell line, harboring a subset of 
cells that are characterized by a ~50kb deletion within AR intron 1 and high-level 
expression of AR-V7 (Li Y et al, 2012 and 2013). These findings strongly implicate AR 
gene rearrangement as the common mechanism for functional AR-V7 expression in these 
cell lines, but this has not been established experimentally. To determine whether the 
intragenic AR rearrangements are sufficient to drive high level AR-V7 expression, we 
used Transcription Activator-Like Effector Nucleases (TALENs) to model AR-V7 
associated rearrangements in an isogenic context (Cermak et al, 2011).   
3.2 Results 
3.2.1 Genetic correction of AR in 22Rv1 
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The CRPC cell line, 22Rv1, harbors a duplication in a region of AR that contains 
exon three as well as the cryptic exons involved in the generation of AR-Vs.  In order to 
determine the significance of this duplication to AR-V expression, we designed a 
TALEN pair, designated tAR2, to bind within the duplicated region (Fig. 3-1 A; Tables 3-
2, 3-3).  We reasoned that simultaneous double-strand breaks, one within and one outside 
the duplication, would delete the intervening sequence, thereby generating a virtually 
normal AR gene structure.   
First, we confirmed the activity of tAR2 with a PCR-digest assay which measures 
non-homologous end joining (NHEJ) mutations introduced within the cleavage site 
located in the spacer sequence between the two TALEN binding sites.  In this instance, 
an Afl III endonuclease site was located in the spacer; error prone NHEJ resulting from 
tAR2 induced dsDNA breaks mutated the Afl III site, causing a PCR product spanning 
this site to be resistant to Afl III digestion (Fig. 3-1 A).  PCR of genomic DNA derived 
from cells expressing tAR2 revealed high levels of mutations derived from NHEJ 
compared to genomic DNA from control cells expressing a vector encoding green 
florescent protein (GFP) (Fig. 3-1 B).  The findings confirm efficient, site-specific 
nuclease activity of tAR2.  
Next, 22Rv1 cells were transfected with tAR2 and plated at limiting dilution in 
order to obtain clonal populations of cells with an excised duplication.  Subclones were 
screened by PCR-digest of the tAR2 cutsite as performed in (Fig 3-1 B); those with a 
wild type band were excluded from further screening.  Clones that did not display wild-
type PCR-digest signal were tested for the presence of the duplication using a multiplex 
ligation-dependent probe assay (MLPA).  This approach yielded four discrete clonal cell 
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lines (B7-5, B34-4, C47-2, and E43-2) that displayed loss of the duplicated genomic 
segment.  One clone, B7-5, could not be characterized further due to an abnormally high 
rate of cell death in culture. 
 
 
3.2.2 Recreating the CWR-R1 intragenic AR deletion in R1-AD1 
 The CWR-R1 cell line harbors a 50kb deletion in intron 1 that is associated with 
AR-V7 overexpression.  In order to establish the role of this rearrangement in AR-V7 
production, we designed a strategy to recreate this deletion in R1-AD1, a sub-line of 
CWR-R1, which contains a structurally normal AR gene and expresses very low levels of 
AR-V7 (Li Y, 2013).  Two TALEN pairs, tAR1-1 and tAR1-2, were designed to created 
double strand breaks flanking the ~50kb region in intron 1 associated with AR-V7 
overexpression (Fig. 3-2 A).  Coordinate action of the TALEN pairs induced two double 
strand breaks which were repaired by NHEJ to create a deletion as detected by deletion-
specific PCR (Fig. 3-2 B).  When tAR1-1 and tAR1-2 were transfected separately, no 
deletions were detected (Fig. 3-2 B).  Next, tAR1-1 and tAR1-2 expressing R1-AD1 cells 
were plated at limiting dilution to isolate subclones harboring the deletion.  Clones were 
then screened for the presence of the deletion as well as cellular purity via genomic PCR 
using primers pairs designed to discriminate between cells with an unmodified AR gene 
locus and cells harboring the targeted deletion.  
Three clones were identified that were positive for the AR intron 1 deletion and 
negative for a wild-type (WT) AR PCR signal.  These discrete cell lines were designated 
R1-dint1a-c (deletion of intron 1) (Fig. 3-2 C, D).  Clones R1-dint1b and R1-dint1c were 
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confirmed to harbor a deletion in intron 1 by MLPA (Fig.3- 2 E).  However, R1-dint1a 
was positive for the MLPA probe signals corresponding to the deleted region.  We 
interpreted these data to indicate that the excised AR intron 1 segment had likely 
integrated elsewhere in the genome.  Consequently, R1-dint1a was excluded from further 
analysis.       
 
 
3.2.3 Effects of intragenic AR rearrangements on AR-V expression. 
Next, western blots were used to determine whether the induced rearrangements 
affected AR-FL and AR-V protein levels.  As AR-FL and AR-V levels may be 
influenced by androgens, we assessed protein expression in steroid-depleted medium 
supplemented with androgens or antiandrogens.  Compared with parental 22Rv1 cells, 
subclones engineered using tAR-2 expressed much lower levels of AR-V7 than 22Rv1, 
suggesting that the duplication is necessary for high levels of AR-V expression (Fig. 3-3 
A).  Additionally, full length AR (AR-FL) levels generally increased under androgenic 
conditions, whereas AR-V levels generally increased under androgen depleted 
conditions.   
22Rv1 also expresses an AR-V, consisting of exons 1-3 and cryptic exon 2b, 
termed 1/2/3/2b (Dehm et al, 2008).  We performed an immunoprecipitation with an 2b 
specific antibody followed by an immunoblot with an amino-terminal AR antibody in 
order to detect the presence of any 2b containing variants.  As expected, reversing the 
duplication eliminated all 1/2/3/2b expression from the modified clones (Fig. 3-3 B).   
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Contrary to expectations, recreating the CWR-R1-associated deletion in R1-AD1 
cells did not induce over-expression of AR-V7 (Fig. 3-3 C).  In contrast with the high 
AR-V7 levels displayed by CWR-R1, R1-AD1 and the subclones all had very low 
expression of AR-V7.  This indicates that the intron-1 deletion is not sufficient for AR-
V7 overexpression. 
 
3.2.4 Effects of intragenic AR rearrangements on growth 
 To characterize the androgen responsive growth of the modified cells, crystal 
violet growth assays were performed in CSS medium containing either 1nM DHT or 
ethanol vehicle.  The 22Rv1 derived lines E43-2 and B34-4 retained androgen responsive 
growth (Fig. 4 A).  In contrast, C47-2 demonstrated androgen-mediated growth repression 
under these culture conditions.  Notably, all cell lines demonstrated some level of 
castration resistant growth. This was expected since there was significant expression of 
AR-V7 (Fig. 3 A).  Additionally, other signaling molecules, such as epidermal growth 
factor receptor (EGFR) (Ateeq et al, 2011), have been shown to contribute mitogenic 
signals in 22Rv1.   
As expected, R1-AD1 and its derived clones displayed androgen responsive 
growth as well as a slower rate of growth under androgen depleted conditions (Fig. 4 B).  
R1-dint1b and R1-dint1c did not recapitulate the androgen independent growth of CWR-
R1, which further suggests the intron 1 deletion is not sufficient to engender an AR-V 
driven mechanism of castration resistance.  
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3.2.5 AR-V7 contributes to full-length AR signaling and castration resistant growth 
Since the 22Rv1 subclones had measureable castration resistant growth, we 
sought to establish whether residual AR-V7 expression in the subclones contributed to 
castration resistant cell growth.  To this end, we measured the relative output of AR 
transcription with a 4xARE-Luciferase reporter in cells co-transfected with siRNAs that 
selectively target full-length vs AR-V7 expression.  Interestingly, AR-V7 contributed to 
the strength of DHT-induced AR-FL signaling (Fig. 5 A,B).  When the non-targeting 
siRNA control group (siCNTL) was compared to the AR-V7 targeting group (siCE3), 
knockdown of AR-V7 decreased luciferase expression under androgenic conditions.  
Interestingly, knockdown of AR-V7 had no effect on luciferase expression in the 22Rv1 
subclones.  In contrast, AR-V knockdown in 22Rv1 reduced luciferase expression. 
To establish the relative roles of AR-V7 and AR-FL in driving castration resistant 
growth, we performed siRNA knockdowns of either AR-FL or AR-V7 in the 22Rv1-
derived cell lines.  The growth of these cells in CSS medium was then measured using 
crystal violet assays.  As expected, siRNA knockdown of AR-V7 significantly reduced 
the growth of 22RV1 and its subclones (Fig. 5 C).  AR-FL also significantly contributed 
to growth in B34-4, E43-2 and, to a lesser extent, 22Rv1.  Interestingly, when growth 
response to androgen stimulation was compared in cells transfected with control siRNA 
or siRNA targeting exon CE3, a greater dynamic response was observed when AR-V7 
expression was silenced (Fig. 5 D).   This indicates that AR-V7 may compensate for sub-
optimal AR-FL signaling in a dose dependent manner and thereby enhance castration 
resistant growth.   
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3.3 Conclusions 
In summary, we demonstrated that a ~50kb deletion in intron 1 of AR, as seen in 
CWR-R1, is not-sufficient to drive high-levels of AR-V7 expression.  However, our data 
indicate that a duplication of a ~35kb region containing exon 3 and cryptic exon CE3 
enforces high-level expression of AR-V7 and 1/2/3/2b.  Intriguingly, significant basal 
expression of AR-V7 in the gene corrected clones indicates that another mechanism of 
AR-V7 over-expression is present in this model system.  Even though the 22Rv1 
subclones had lower levels of AR-V7 expression, AR-V7 still contributed to AR 
signaling and CRPC growth.  Importantly, AR-V expression patterns in the gene 
corrected 22Rv1 clones are similar to levels seen in patient-derived CRPC tissues 
(Jernberg et al, 2013; Hornberg et al, 2011).   
The mechanism of basal AR-V7 expression is unknown.  One possibility is that 
AR-V7 expression is related to global changes in alternative splicing commonly found in 
cancers (Bonomi et al, 2013).  Splice factors U2AF65 and ASF/SF2 were shown to bind 
to a splice enhancer site that regulates AR-V7 expression (Liu et al, 2013).  However, it 
is unclear how these factors are involved in the pathogenic overexpression of AR-V7.  
Therefore, further characterization of the expression and post-translational modification 
of U2AF65 and ASF/SF2 in AR-V7 overexpressing cell lines is necessary for 
establishing their role in exon CE3 splicing.    
 
3.4 Methods 
Multiplex Ligation-dependent Probe Amplification:  Assays were performed as 
described previously (Li Y et al, 2012). 
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 Cell growth assays:  Crystal violet growth assays were performed as previously 
described (Li Y et al, 2011).  Briefly, cells were electroporated with 200 pmoles siRNA 
as previous described (Li Y et al, 2013).  The electroporated cells were plated in 24 well 
plates at 2.5*10^4 cells per well in RPMI 1640 supplemented with 10% charcoal stripped 
serum (CSS).  After 24 hours, media was replaced with RPMI + 10% CSS supplemented 
with 1nM DHT or vehicle control (ethanol).  
 
Genomic DNA PCR:   Genomic DNA was isolated using Nucleospin tissue kit (Catalog 
740952, Machery-Nagel).  Genomic DNA was amplified using Phusion-HF (M0530S 
New England Biolabs, Ipswich, MA) according to the manufacturer’s protocol.  Primers 
used in PCR reaction are listed in Table 3-1. Products were cloned and sequenced as 
previously described (Nyquist et al, 2013) 
 
Genomic PCR digest: 
Genomic DNA was isolate and amplified as described earlier (see Genomic DNA PCR).  
Genomic PCR products were column purified with Qiaquick PCR purification kit (28104 
Qiagen. Valencia, CA).  Next, 500ng of PCR product was then digested with 10 units of 
Afl III (R0541S New England Biolabs, Ipswich, MA) for 2 hours then run on an agarose 
gel. 
 
Construction of TALENS:  TALEN construction was carried out as previously 
described. (Cermak et al, 2011; Nyquist et al, 2013) 
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Immunoprecipitation and Western Blots:  Immunoprecipitations and western blots 
were performed as previously described (Li Cancer Res 2011; Chan et al, 2012).  
Antibodies used in this study include: anti-AR NTD polyclonal (N-20, Santa Cruz 
Biotechnology), anti-ERK2 monoclonal (D-2), Santa Cruz Biotechnology), anti-AR NTD 
monoclonal (AR-441, Santa Cruz Biotechnology), anti-AR-V7 monoclonal (AG10008, 
Precision Antibody) and a polyclonal antibody specific for the COOH-terminal extension 
encoded by AR exon 2b (Chan et al, 2012). 
 
Lucifierase Assay:  Dual luciferase assays were performed with a 4X-ARE luciferase 
reporter (A gift from Dr. Michal Carey, University of California, Los Angeles) and a 
SV40-renilla reporter (Promega) for transfection control as previously described (Dehm 
et al, 2008)  
 
Cell lines and Cell Culture: Androgen-responsive R1-AD1 prostate cancer cells with a 
structurally normal AR gene locus has been described (Li Y et al, 2013; Nyquist et al, 
2013). Cell lines 22Rv1 (CRL-2505) and LNCaP (CRL-1740) were obtained from ATCC 
(Manassas, VA, USA).  Cells were maintained in RPMI 1640 with 10% FBS in a 5% 
CO2 incubator at 37OC 
 
Generation of Cell Lines: To generate R1-AD1 derived 48kb intron 1 deletion lines, 
TALENs tAR1-1 and tAR1-2 were electroporated into R1-AD1 as previously described 
(Nyquist et al, 2013) and allowed to recover in RPMI 1640 media containing 10% FBS.  
Cells were single cell cloned by seeding at limiting dilution in 10cm dishes. Cells were 
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screened using a deletion specific PCR with primer pairs ARint1 F1 and ARint R2.  To 
generate 22Rv1 subclones without a duplication, cells were electroporated and seeded at 
limiting dilution as described above. Next, cells were screened with PCR-digest to detect 
an intact Afl III binding site in the tAR2 spacer sequence.  Clones without an intact Afl 
III were further screened by MLPA.   
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3.5 Figures 
Figure 3-1 TALEN mediated genetic correction of the duplication in 22Rv1. 
 
Figure 3-1 (A) Gene structure of wild type AR (WT-AR) in comparison to that of 22Rv1.  
Cryptic exons are marked 2b and CE1-3.  Red arrows mark the tAR2 TALEN binding 
sites.  The endonuclease target site of Afl III is present at the tAR2 binding site (B) PCR 
digest indicating tAR2 induced mutations.  The tAR2 cutsite was amplified by PCR and 
digested with Afl III.  TALEN activity followed by NHEJ repair induces mutations in the 
Afl III binding site which is indicated but an uncut PCR product of ~700bp.  GFP is the 
negative control. (C) MLPA of AR locus of 22Rv1 and its subclones.  AR gene locus is 
shown with MLPA probe sites.  Primer sequences are listed in TABLE 3-1. 
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Figure 3-2 Modeling the CWR-R1 AR gene rearrangement in R1-AD1.   
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Figure 3-2  (A) Gene structure of wild-type AR in comparison to that of CWR-R1.  The 
TALEN pairs tAR1-1 and tAR1-2 are indicated with red arrows.  Primer binding sites F1, 
R1, and R2 are indicated with black arrows. (B) Deletion spanning genomic PCR with 
primers designed to detect tAR2-mediated intragenic deletion in AR intron 1.  (C)  
Genomic PCR with primers designed to discriminate between clonal sublines harboring 
an unmodified AR locus and clonal sublines harboring tAR2-mediated intragenic deletion 
in AR intron 1.(D) Genomic sequences of the deletion break fusion junctions  in clonal 
sublines derived from tAR2-mediated genome engineering. (E) MLPA-based 
interrogation of genomic copy number at distributed sites along the length of the AR 
genein clonal sublines derived from tAR2-mediated genome engineering.  Primer 
sequences are listed in TABLE 3-1. 
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Figure 3-3 Rearrangement driven effects on AR-V7 expression 
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Figure 3-3 (A) AR-NTD and AR-V7 Western blot of 22Rv1 and gene-corrected 
subclones.  Cells were cultured for four days in RPMI-1640 media + 10% charcoal 
stripped serum (CSS) and either 1nM dihydrotestosterone (DHT), 10uM enzalutamide 
(Enz), or ethanol (EtOH) vehicle.  Blots were probed with an anti-AR NTD polyclonal 
antibody or an anti-AR-V7 mono-clonal antibody.   ERK2 functioned as the loading 
control.  (B)  Immunoprecipitation-western blots of 22RV1, gene corrected 22Rv1 
subclones, and LnCaP lysates for AR-V species 1/2/3/2b.  (C) AR-NTD and AR-V7 
western blot of R1-AD1, subclones with a 50kb intron-1 deletion, and CWR-R1 (late 
passage).  As in panel A,  cells were cultured for four days in RPMI-1640 media + 10% 
charcoal stripped serum (CSS) and either 1nM dihydrotestosterone (DHT), 10uM 
enzalutamide (Enz), or ethanol (EtOH) vehicle.  Blots were probed with an anti-AR NTD 
polyclonal antibody or an anti-AR-V7 mono-clonal antibody.   ERK2 functioned as the 
loading control. 
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 Figure 3-4 Androgen dependent growth of AR gene modified cell lines 
 
 
 
Figure 3-4 (A) Six day crystal violet growth curve of 22Rv1 and AR gene corrected 
subclones.  Cells were grown in RPMI-1640 + 10% CSS with either 1nM DHT or 
ethanol vehicle.  Error bars represent standard deviation of the mean. These data are 
derived from a quadruplicate experiment representative of two independent biological 
replicates (n=4). Asterisks indicate p-values < 0.05.  (B) Four day crystal violet growth 
assays of R1-AD1 and gene modified subclones.  Cells were grown in RPMI-1640 + 10% 
CSS with either 1nM DHT or EtOH vehicle.  Error bars represent standard deviation of 
the mean.  These data are derived from a sextuplet experiment representative of two 
independent biological replicates (n=6). Asterisks indicate p-values < 0.05.   
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 Figure 3-5 AR-V7 enhances AR-FL signaling and contributes to androgen-independent 
growth in a dose dependent manner. 
 
 
 
91 
 
Figure 3-5 AR-V7 enhances AR-FL signaling and contributes to androgen-independent 
growth.  (A) AR transcriptional activity in 22Rv1 and modified subclones is indicated by 
induction of the 4xARE-luciferase reporter in response to 1nM DHT or EtOH vehicle.  
Luciferase signals were normalized to a co-transfected SV40-Renilla reporter.  Cells were 
transfected with the reporters and siRNAs targeting AR-FL (siExn7), AR-V7 (siCE3), or 
a non-targeting control (siCNTL).  Error bars represent standard deviation.  These data 
are derived from a quadruplicate experiment representative of two independent biological 
replicates (n=4).  Asterisks indicate p-values < 0.05 in comparison to control.  (B) 
Western blots confirming knockdown of AR-FL or AR-Vs.  (C) Crystal violet growth 
assays of 22Rv1 and subclones under androgen deplete culture conditions with siRNA 
knockdowns.  Error bars represent standard error.  These data represent two combined 
biological replicates (n=8). Asterisks indicate p-values < 0.05.  (D) The magnitude of 
androgen induced growth is plotted as the (fold androgenic growth) / (fold castrate 
growth).   Cells were transfected with either siCNTL or siCE3 then cultured for six days 
in RPMI-1640 + 10% CSS media with either 1nM DHT or EtOH.  Cell growth was 
determined by crystal-violet staining.  Error bars represent standard error.  These data are 
two combined biological replicates (n=8). Asterisks indicate p-values < 0.05 when 
compared to control conditions.   
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3.6 Tables  
Table 3-1 Primers used in study 
Genomic 
PCR       
AR Int2 F1 ctcccaacaagtgatcagtagtcagaaaatgg     
AR Int2 R1 caacagggtatcttattttgcaaaccctaagtc     
AR Int1 F1 gaagtgactgcatatcacgtcatg     
AR Int1 R1 gaattactgacaccaacccaaagc     
AR Int1 R2 caagtccaacacagtttccattacc     
 
Table 3-2 TALEN targets 
TALENs Target 
tAR2 gaacattcctgcctggctgacatgtggactctctgaaattgttat 
    
tAR1-1 ctacttcagtcctttcccacccagctggtttaggaatcaaattccca 
    
tAR1-2 agcatttagctgaattatatattggaagtaagctccttccatgtgg 
    
 
Table 3-3 TALEN design 
RVD position 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 
tAR2 Left NN NI NI HD NI NG NG HD HD NG NN HD HD NG NN   
tAR2 Right NI NG NI NI HD NI NI NG NG NG HD NI NN NI NN   
tAR1-1 Left HD NG NI HD NG NG HD NI NN NG HD HD NG NG NG   
tAR1-1 Right NG NN NN NN NI NI NG NG NG NN NI NG NG HD HD NG 
tAR1-2 Left NI NN HD NI NG NG NG NI NN HD NG NN NI NI NG NG 
tAR1-2 Right HD HD NI HD NI NG NN NN NI NI NN NN NI NN HD NG 
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